The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
The Standard Care vs. COrticosteroid for  
REtinal Vein Occlusion (SCORE) Study 
 
 
Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) 
of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for 
Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion  
 
 
 
Version 7.0 — February 10, 2008 
 
Study Chair       Study Co- Chair  
Michael S. Ip, MD      Ingrid U. Scott, MD, MPH  
University of Wisconsin Medical School   Professor of Ophthalmology and 
Dept of Ophthalmology and Visual Sciences   Health Evaluation Sciences  
F4/336 Clinical Science Center     Penn State College of Medicine  
600 Highland Avenue      500 University Drive, HU19  
Madison, WI  53792     Hershey, PA  17033 
Tel:  608 -263-4823     Tel:  717-531-5368 
Fax: 608- 263-1466     Fax:  717- 531-5475 
E-mail:  msip@facstaff.wisc.edu    E- mail:  iscott@psu.edu  
 
Principal Investigator      Principal Investigator  
Data Coordinating Center     Fundus Photograph Reading Center  
Paul C. VanVeldhuisen, PhD    Barbara A. Blodi, MD  
The EMMES Corporation    406 Science Drive, Suite 400 
401 N. Washington Street, Suite 700   Madison, WI  53711 
Rockville, MD  20850- 1785    Tel:  608-263-7290 
Tel:  301 -251-1161 x143    Fax: 608- 263-1466 
Fax: 800-546-9262     E-mail:  bablodi@facstaff.wisc.edu  
E-mail:  pvanveldhuisen@emmes.com  
 NEI Program Officer      DSMC Chair  
Maryann Redford, DDS, MPH    John Connett, PhD 
National Eye Institute      University of Minnesota  
6120 Executive Blvd., Suite 350   Coordinating Centers for Biometric Research  
Bethesda, MD  20892     2221 University Avenue SE, Room 200 
Tel:  301 -451-2020     Minneapolis, MN  55414 
Fax: 301- 402-0528     Tel:  612 -626-9010 
E-mail:  maryann.redford@nei.nih.gov
   Fax: 612- 626-9054 
       E- mail:  john- c@blueox.ccbr.umn.edu  
 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
i Table of Contents 
PRÉCIS  .................................................................................................................................... 1 
1. INTRODUCTION................................................................................................................ 3 
2. BACKGROUND AND SCIENTIFIC JUSTIFICATION  ................................................ 3 
2.1 Venous Occlusive Disease .................................................................................................... 3 
2.2 Pathogenesis of Macular Edema  ......................................................................................... 6 
2.3 Animal and Clinical Studies Using Intravitreal Triamcinolone Acetonide Injections  .. 8 
2.4 Other Studies Evaluating Corticosteroid Preparations Other Than Triamcinolone 
Acetonide for Treatment of Macular Edema due to Retinal Vascular Disease ........... 16 
2.4.1 Efficacy  ..................................................................................................................... 16 
2.4.2 Adverse Effects  ......................................................................................................... 17 
2.5 Rationale for the Intravitreal Triamcinolone Acetonide Doses to be Evaluated ......... 18 
2.6 Mechanism of Adverse Effects Associated with Intravitreal Steroids  .......................... 20 
2.6.1 Elevation of Intraocular Pressure .............................................................................. 20 
2.6.2 Cataract Formatio n .................................................................................................... 21 
2.6.3 Endophthalmitis ........................................................................................................ 22 
3. OBJECTIVES  .................................................................................................................... 24 
4. STUDY DESIGN AND METHODS ................................................................................. 24 
4.1 Efficacy Assessment  ........................................................................................................... 25 
4.1.1 Primary Efficacy Outcome ........................................................................................ 25 
4.1.2 Secondary Efficacy Outcomes  .................................................................................. 25 
4.2 Safety Assessments ............................................................................................................. 26 
4.2.1 Safety Outcomes  ....................................................................................................... 26 
4.3 Inclusion Criteria  ............................................................................................................... 26 
4.3.1 General Inclusion Criteria  ......................................................................................... 26 
4.3.2 Ocular Inclusion Criteria  (study eye)  ........................................................................ 26 
4.4 Exclusion Criteria  .............................................................................................................. 28 
4.4.1 General Exclusion Criteria  ........................................................................................ 28 
4.4.2 Ocular Exclusion Criteria (study eye)  ....................................................................... 29 
4.4.3 Fellow (Non -Study) Eye Criteria (the Fellow Eye Must Meet the Following)  ......... 31 
4.5 In
formed Consent, Screening Evaluation, and Randomization .................................... 32 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
ii 4.5.1 Informed Consent ...................................................................................................... 32 
4.5.2 Screening Evaluation  ................................................................................................ 32 
4.5.3 Randomization .......................................................................................................... 34 
4.6 Standard Care Groups  ...................................................................................................... 35 
4.6.1 Photocoagulation Procedures .................................................................................... 35 
4.7 Intravitreal Steroid Groups  .............................................................................................. 36 
4.7.1 Intravitreal Injection of Triamcinolone Acetonide.................................................... 36 
4.8 Participant Visit Schedule, Retreatment, Alternate Treatment and Other Treatments 37 
4.8.1 Visit Schedule  ........................................................................................................... 37 
4.8.2 Testing Procedures to be Performed at Follow-up Visits (see Appendix 1) ............. 38 4.8.3 Retreatment Assessment  ........................................................................................... 39 
4.8.4 Alternate Treatment for the Study Eye  ..................................................................... 42 
4.8.5 Other Treatments  ...................................................................................................... 43 
4.9 Diagnosis and Treat ment of Adverse Events  ................................................................... 43 
4.9.1 Endophthalmitis Treatment ....................................................................................... 43 
4.9.2 Treatment of Elevated Intraocular Pressure (IOP)  .................................................... 43 
4.9.3 Cataract Surgery  ........................................................................................................ 44 
4.9.4 Surgery for Proliferative Retinopathy and Other Complications Due to Retinal Vein 
Occlusion  ................................................................................................................. 45 
4.10 Miscellaneous Treatments During Follow -up ................................................................. 46 
4.10.1 Treatment of Macular Edema in Non -study Eye  ...................................................... 46 
4.10.2 Panretinal Photocoagulation (PRP) Treatment: ........................................................ 46 
5. DATA MONITORING AND ADVERSE EVENT REPORTING  ................................ 47 
5.1 Data Safety Monitoring Committee ................................................................................. 47 
5.2 Methods and Timing for Assessing, Recording and Analyzing Safety Parameters .... 48 
5.3 Procedures for Reporting Adverse Events  ...................................................................... 49 
5.3.1 Routine SCORE DCC Review  ................................................................................. 49 
5.3.2 Adverse Event Severity Grading ............................................................................... 51 5.3.3 Relation to Therapy ................................................................................................... 52 5.3.4 Adverse Event Reporting Requirements and Procedures for Clinical Sites to the 
SCORE Coordinating C enter  ................................................................................... 52 
5.3.5 R
eporting Procedures ................................................................................................ 53 
5.3.6 SCORE Adverse Event Reporting Contact ............................................................... 53 
5.4 Procedure for Reporting of Pregnancy  ............................................................................ 54 
6. STATISTICAL CONSIDERATIONS  ............................................................................. 54 
6.1 Scientific and Regulatory  Objectives  ............................................................................... 54 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
iii 6.2 Formal Regulatory Statistical Test of Efficacy ............................................................... 55 
6.3 Scientific Statistical Approach  .......................................................................................... 56 
6.3.1 Two Independent Clinical Trials ............................................................................... 56 
6.3.2 Three Primary Questions in Each Clinical Trial ....................................................... 56 
6.4 Assumptions for and Result of Sample Size Estimation................................................. 58 
6.4.1 Study Power .............................................................................................................. 58 6.4.2 Estimate of CRVO Primary Eff icacy Outcome in the Standard Care Group  ........... 58 
6.4.3 Estimate of BRVO Primary Efficacy Outcome in the Standard Care Group  ........... 58 
6.4.4 Background Information on Efficacy of I ntravitreal Injection(s) of Triamcinolone 
Acetonide ................................................................................................................. 59 
6.4.5 Sample Size Estimate  ................................................................................................ 60 
6.5 Safety Outcomes  ................................................................................................................. 61 
6.6 Secondary Efficacy Outcomes  .......................................................................................... 62 
6.7 Statistical Guidelines for Interim Monitoring by the DSMC  ........................................ 63 
6.7.1 Interim Monitoring for Safety  ................................................................................... 63 
6.7.2 Interim Monitoring for Efficacy  ................................................................................ 63 
6.7.3 Interim Monitoring for Futility  ................................................................................. 64 
6.7.4 Analyses and Results Requested to be Considered Prior to Recommending Early 
Termination  .............................................................................................................. 64 
6.7.5 Study Timeline and DSMC Data Reviews  ............................................................... 65 
7. CONFIDENTIALITY AND ACCESS TO SOURCE DATA / DOCUMENTS  ........... 66 
8. SUMMARY OF GOOD CLINICAL PRACTICE COMPLIANCE  ............................. 66 
8.1 Investigator Responsibilities (Form FDA-1572) .............................................................. 66 
8.2 Human Subjects Protection ............................................................................................... 67 
8.2.1 Institutional Review Board or Independent Ethics Committee ................................. 67 
8.3 Data Handling and Recordkeeping  .................................................................................. 68 
8.3.1 Case Report Forms  .................................................................................................... 68 
8.3.2 Data Transmittal ........................................................................................................ 68 
8.4 Professional Licensure ....................................................................................................... 69 
8.5 Human Subjects Protection Training  .............................................................................. 69 
9. REFERENCES  ................................................................................................................... 70 
10. APP
ENDIX I  ...................................................................................................................... 74 
 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
iv  
Note:  A separate Manual of Policies and Procedures (MOPP) developed to accompany this 
protocol will provide additional details and guidance on study operational activities.  A Data Management Handbook (DMH) will provide details for data collection procedures and data quality management procedures.  Participating sites will be provided the necessary instructions and review of the protocol, MOPP and DMH during site visits and/or at investigator meetings.  The current master protocol (incorporating any approved amendments), MOPP, and DMH are always accessible to authorized study staff via the SCORE Study web page at http://www.emmes.com/
, where a username and password are required for access.  
 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 1 Précis 1 
Macular edema is a major cause of vision loss in patients with central retinal vein occlusion 2 
(CRVO) and branch retinal vein occlusion (BRVO).  Currently, there is no effective treatment for 3 
macular edema associated with CRVO.  For macular edema associated with BRVO, grid laser 4 
photocoagulation may be an effective treatment, but many patients derive limited benefit from 5 
this treatment.  Therefore, the development of new treatment modalities to treat macular edema 6 
caused by these tw o conditions is an important research goal.  The Standard Care vs. 7 
COrticosteroid for REtinal Vein Occlusion (SCORE) Study will compare the efficacy and safety 8 
of standard care with intravitreal injection(s) of triamcinolone acetonide to treat macular edema 9 
associated with CRVO and BRVO.  10 
 11 
The SCORE Study is designed as a multicenter, randomized, Phase III trial to compare the 12 
efficacy and safety of standard care versus triamcinolone acetonide injection(s) for the treatment 13 
of macular edema associated with C RVO and BRVO.  In each of the two disease areas, 486 14 
participants will be randomized in a 1:1:1 ratio to one of three groups: standard care, intravitreal 15 
triamcinolone 4 mg, or intravitreal triamcinolone 1 mg.  For CRVO participants, standard care 16 
consists of observation of the macular edema.  For BRVO participants, standard care consists of 17 
immediate grid laser photocoagulation for study eyes without a dense macular hemorrhage.  For 18 
study eyes of BRVO participants with a dense macular hemorrhage, standard care is observation 19 
followed by grid laser photocoagulation if and when clearing of the hemorrhage permits grid 20 
laser photocoagulation.  For all three groups, neovascular complications will be treated as 21 
necessary.  Repeat treatments will be provided as cl inically indicated based on protocol- specific 22 
guidelines.  Participants will be followed for between 1 and 3 years after randomization.  The 23 
primary efficacy outcome of this study is improvement by 15 or more letters from baseline in 24 
best-corrected ETDRS visual acuity score at the 12 -month visit.  Secondary efficacy outcomes 25 
include change between baseline and each efficacy outcome assessment visit in best -corrected 26 
ETDRS visual acuity score, change in retinal thickness at the center of the macula and change in 27 
area of retinal thickening as assessed by stereoscopic color fundus photography, and change in 28 
retinal thickness and calculated retinal thickening as assessed by optical coherence tomography.  29 
Safety outcomes include injection -related adverse events s uch as infectious endophthalmitis, 30 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 2 non-infectious endophthalmitis, retinal detachment, and vitreous hemorrhage and steroid- related 31 
adverse events, which include cataract and elevated intraocular pressure.  32 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 3 1. Introduction 33 
Central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) are common 34 
retinal vascular diseases.  Macular edema from these two conditions is a frequent cause of vision 35 
loss and remains a major public health problem.  Furthermore, current treatment modalities for 36 
macular ed ema resulting from these conditions are often unsatisfactory.  At present, there is no 37 
effective treatment for macular edema from CRVO.  Grid laser photocoagulation for macular 38 
edema from BRVO may, in many cases, be an effective treatment.  However, many p atients 39 
derive limited benefit from this treatment.  A number of new treatment modalities are being 40 
developed.  The majority of these is either based on complex surgical procedures or is associated 41 
with increased cost.  The Standard Care vs. CO rticosteroid  for REtinal Vein Occlusion (SCORE) 42 
Study proposes to investigate the less expensive and relatively less invasive treatment of 43 
intravitreal injection(s) of triamcinolone acetonide for this frequent cause of visual impairment in 44 
patients with CRVO and BRVO.  45 
 46 
The potential adverse effects of corticosteroids include cataract and elevated intraocular pressure 47 
(IOP).  Delivery of corticosteroids via intravitreal injection adds potential injection -related risks 48 
of retinal detachment, vitreous hemorrhage, infectious endophthalmitis, and non-infectious 49 
endophthalmitis.  As a result of these risks, further investigation is warranted to evaluate the risks 50 
of this treatment modality compared with the potential benefits.  The risks associated with 51 
intravitreal injection (s) of corticosteroids may be acceptable given the opportunity to reverse 52 
vision loss from macular edema associated with CRVO or BRVO. 53 
 54 
2. Background and Scientific Justification 55 
2.1 Venous Occlusive Disease 56 
CRVO and BRVO are common retinal vascular disorders.  BRVO has been reported to be 57 
second only to diabetic retinopathy in the frequency with which it produces retinal vascular 58 
disease.1  CRVO and BRVO have a characteristic appearance with intraretinal hemorrhage, 59 
tortuous and dilated retinal veins and, occasionally, optic disc edema.  Macular edema is a 60 
frequent cause of visual acuity loss in eyes with CRVO and BRVO.1-4  61 
 62 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 4 In the Central Vein Occlusion Study (CVOS) 728 eyes with CRVO were studied.2  Of these 63 
728 eyes, 155 (21%) had macular edema that reduced visual acuity to 20/50 or worse 64 
(group M eyes, macular edema).  In the largest group (group P, perfused) that included 547 65 
eyes, 84% (460 eyes) had angiographic evidence of macular edema involving the fovea at 66 
baseline.  67 
 68 
The natural history of macular edema associated with CRVO was delineated in the CVOS.2-4 69 
Additionally, the group M arm of the CVOS evaluated the treatment of macular edema with 70 
grid laser photocoagulation in 155 eyes (77 treated eyes and 78 control eyes) over a 3 year 71 
follow-up period.  All eyes had macular edema for a minimum of 3 months prior to 72 
enrollment.  For untreated eyes with an initial visual acuity between 20/50 and 5/200 at 73 
presentation (n=78 eyes), 42 eyes were available for follow-up at the 3- year visit.  Of these 74 
eyes, 10 (24%) gained two or more lines of visual acuity at the 3- year follow -up.  Twenty 75 
eyes (48%) remained within two lines of baseline visual acuity and 12 eyes (29%) lost two or 76 
more lines of visual acuity at the 3 -year follow -up.  At the 3- year follow -up, six eyes (14%) 77 
gained three or more lines of visual acuity.  Thirty eyes (71%) remained within three lines of 78 
baseline visual acuity and six eyes (14%) lost three or more lines of visual acuity at the 3- 79 
year follow -up.  The final median visual acuity in untreated eyes was 20/160. 80 
 81 
At the 2 -year visit, 53 untreated eyes were available for follow -up.  Of these eyes, 10 (19%) 82 
gained two or more lines of visual acuity.  Thirty-one eyes (58%) remained within two lines 83 
of baseline visual acuity and 12 eyes (23%) lost two or more lines of visual acuity at the 2 - 84 
year follow -up.  At the 2- year follow -up, 6 eyes (11%) gained three or more lines of visual 85 
acuity.  Thirty -nine eyes (74%) remained within three lines of baseline visual acuity and 86 
eight eyes (15%) lost three or more lines of visual acuity at the 2 -year follow -up. 87 
 88 
At the 1 -year visit, 72 untreated eyes were available for follow -up.  Of these eyes, 6 (8%) 89 
gained two or more lines of visual acuity.  Forty-four eyes (61%) remained within two lines 90 
of baseline visual acui ty and 22 eyes (31%) lost two or more lines of visual acuity at the 1- 91 
year follow -up.  At the 1- year follow -up, 4 eyes (6%) gained three or more lines of visual 92 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 5 acuity.  Fifty -nine eyes (82%) remained within three lines of baseline visual acuity and nine 93 
eyes (13%) lost three or more lines of visual acuity at the 1- year follow -up. 94 
 95 
The CVOS found no significant difference in visual outcome between the treatment and 96 
observation groups at any follow-up point.  Although there was a definite decrease in 97 
macular  edema on fluorescein angiography in the treatment group when compared to the 98 
control group, this did not translate to a direct visual improvement.4  Therefore, at present, 99 
there is no proven therapy for visual impairment due to macular edema associated with 100 
CRVO.  Thus, it is important to explore other avenues for managing this potentially 101 
devastating cause of vision loss. 102 
 103 
The Branch Vein Occlusion Study (BVOS) reported on the natural history of macular 104 
edema associated with BRVO.1 All eyes had macular ed ema for 3 to 18 months prior to 105 
study entry; eyes with obvious areas of capillary nonperfusion in the macula were excluded 106 
from the study.  After 3 years, of 35 untreated eyes available for follow-up, only 12 eyes 107 
(34%) with a presenting visual acuity of 20/40 or worse achieved a visual acuity of 20/40 or 108 
better.  Furthermore, eight eyes (23%) had 20/200 or worse visual acuity at the final 3- year 109 
follow-up visit. 110 
 111 
The group III arm of the BVOS was designed to evaluate grid photocoagulation treatment 112 
of macular edema due to BRVO that had persisted for at least 3 -months (and less than 18 113 
months) in eyes with visual acuity of 20/40 or worse.  One hundred thirty nine eyes (71 114 
treated eyes and 68 control eyes) were studied.  This arm of the study did demonstrate a 115 
benefit for eyes treated with macular grid photocoagulation.1 Of 43 treated eyes available 116 
for follow -up at the 3-year visit, 28 eyes (65%) had gained two or more lines of visual 117 
acuity from baseline and maintained this gain for at least eight months, as  compared with 118 
the same gain in 13 of 35 (37%) untreated eyes. At the 3- year visit, nearly twice as large a 119 
proportion of treated vs. control eyes had visual acuity of 20/40 or better. 120 
 121 
Although the BVOS did demonstrate a visual acuity benefit for eyes tre ated with grid 122 
photocoagulation, the BVOS also identified a subset of patients that derive limited benefit 123 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 6 from macular grid photocoagulation.  In the BVOS, 40% of treated eyes (n=43) had worse 124 
than 20/40 vision at 3 years and 12% of treated eyes had 20/200 or worse visual acuity at 3 125 
years.1 Therefore, for some patients with macula edema associated with BRVO current 126 
treatment options are limited and other treatment options should be sought.  For example, 127 
surgical decompression of BRVO via arteriovenous crossing sheathotomy has been 128 
investigated.5 However, this is an invasive surgical intervention with inherent risks, 129 
recovery time and expense.  As a result, there is interest in exploring treatment options such 130 
as intravitreal injection(s) of triamcinolone a cetonide.  Table 1 summarizes visual acuity 131 
data from the two randomized clinical trials discussed above in which the natural history of 132 
macular edema from CRVO and BRVO was evaluated.  133 
 134 
Table 1:  Natural history of macular edema in two randomized 135 
trials of patients with retinal vein occlusion  136 
 137 
Study  Vision 
improved by 2 
or more lines Vision 
unchanged 
(± 2 lines) Vision worse by 
2 or more lines Number of 
eyes at end 
of study 
period  Follow -
up period  
  
%  
No.  
%  
No.  
%  
No.   
CVOS  24% 10 48% 20 29% 12 42 3 years  
CVOS  19% 10 58% 31 23% 12 53 2 years  
CVOS  8% 6 61% 44 31% 22 72 1 year  
CVOS* 6% 4 82% 59 13% 9 72 1 year  
BVOS  
 37% 13 46% 16 17%   6 35 3 years  
 * Improvement or worsening of vision by 3 or more lines 138 
CVOS  Central Vein Occlusion Study 139 
BVOS  Branc h Vein Occlusion Study 140 
 141 
2.2 Pathogenesis of Macular Edema  142 
Macular edema from venous occlusive disease results from the initial insult of thrombus 143 
formation at the lamina cribrosa or an arteriovenous crossing.  Green et al, in a 144 
histopathologic study of 29 eyes with CRVO, documented a fresh or recanalized thrombus 145 
of the central retinal vein in the area of the lamina cribosa as a constant pathologic finding.6 146 
Frangieh et al, in a histopathologic study of nine eyes with BRVO, documented a fresh or 147 
recanalized  thrombus at the site of vein occlusion in all eyes studied.7 Experimental work in 148 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 7 animals has demonstrated that following venous occlusion, a hypoxic environment in the 149 
retina is produced.8 This is then followed by functional, and later structural changes, in the 150 
retinal capillaries.  These changes resulted in an immediate increase in retinal capillary 151 
permeability and accompanying retinal edema.  152 
 153 
The increase in retinal capillary permeability and subsequent retinal edema may be the 154 
result of a breakdown of the blood retina barrier mediated in part by vascular endothelial 155 
growth factor (VEGF), a 45 kD glycoprotein.9 Aiello et al demonstrated in an in vivo 156 
model, that VEGF can increase vascular permeability.9  Fifteen eyes of 15 albino Sprague- 157 
Dawley rats received an intravitreal injection of VEGF.  The effect of intravitreal 158 
administration of VEGF on retinal vascular permeability was assessed by vitreous 159 
fluorophotometry.  In all 15 eyes which received an intravitreal injection of VEGF, a 160 
statistically significant increase in vitreous fluorescein leakage was recorded.  In contrast, 161 
control eyes, which were fellow eyes injected with vehicle alone, did not demonstrate a 162 
statistically significant increase in vitreous fluorescein leakage.  Vitreous fluorescein 163 
leakage in eyes injected with VEGF attained a maximum of 227% of control levels.  164 
Antonetti et al demonstrated that VEGF may regulate vessel permeability by increasing 165 
phosphorylation of tight junction proteins such as occludin and zonula occluden 1.10  166 
Sprague-Dawley rats were given intravitreal injections of VEGF and changes in tight 167 
junction proteins were observed through Western blot analysis.  Treatment with alkaline 168 
phosphatase revealed that these changes were caused by a change in phosphorylation of 169 
tight junction proteins.  This model provides, at the molecular level, a potential mechanism 170 
for VEGF -mediated vascular permeability in the eye.  Similarly, in human non -ocular 171 
disease states such as ascites, VEGF has been characterized as a potent vascular 172 
permeability factor (VPF).11 173 
 174 
The normal human retina contains little or no VEGF; however, hypoxia causes 175 
upregulation of VEGF production.12 Disease states characterized by hypoxia-induced 176 
VEGF upregulation include CRVO and BRVO.9,12  Vinores et al, using 177 
immunohistochemical staining for VEGF, demonstrated that increased VEGF staining was 178 
found in retinal neurons and retinal pigment epithelium in human eyes with venous 179 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 8 occlusive disease.12  Pe’er et al, evaluated 10 human eyes enucleated for neovascular 180 
glaucoma from CRVO and used molecular localization with a VEGF-specific probe to 181 
identify cells producing VEGF messenger RNA (mRNA).13  All of these eyes demonstrated 182 
upregulated VEGF mRNA expression in the retina.  This hypoxia-induced upregulation of 183 
VEGF m ay be inhibited pharmacologically.  Adamis et al demonstrated in a nonhuman 184 
primate model that anti-VEGF antibodies can inhibit VEGF driven capillary endothelial 185 
cell proliferation.14 In this study, 16 eyes of nonhuman primates had retinal ischemia 186 
induced by laser retinal vein occlusion.  Zero of eight eyes receiving neutralizing anti- 187 
VEGF antibodies developed iris neovascularization while five of eight control eyes 188 
eventually developed iris neovascularization. 189 
 190 
As the above discussion suggests, attenuation of the effects of VEGF introduces a rationale 191 
for treatment of macular edema from venous occlusive disease.  Corticosteroids, a class of 192 
substances with anti-inflammatory properties, have been demonstrated to inhibit the 193 
expression of the VEGF gene.15 In a study by Nauck et al, the platelet -derived growth- 194 
factor (PDGF) induced expression of the VEGF gene in cultures of human aortic vascular 195 
smooth muscle cells was inhibited by corticosteroids in a dose-dependent manner.15 A 196 
separate study by Nauck et al d emonstrated that corticosteroids downregulated the 197 
induction of VEGF by the pro- inflammatory mediators PDGF and platelet- activating factor 198 
(PAF) in a time and dose-dependent manner.16  This study was performed using primary 199 
cultures of human pulmonary fibroblasts and pulmonary vascular smooth muscle cells. 200 
 201 
2.3 Animal and Clinical Studies Using Intravitreal Triamcinolone Acetonide 202 
Injections  203 
Intravitreal injection of triamcinolone acetonide has been shown to be non- toxic in animal 204 
studies.17-19 McCuen et al inj ected 1mg of triamcinolone acetonide into the vitreous cavity 205 
of 21 rabbit eyes.17  Throughout the 3-month course of follow-up ophthalmoscopy, IOP, 206 
electroretinography (scotopic and photopic responses) and light and electron microscopy all 207 
remained normal.   Schindler et al studied the clearance of intravitreally injected 208 
triamcinolone acetonide (0.5 mg) in 30 rabbit eyes.18 In non- vitrectomized eyes the average 209 
clearance rate was 41 days.  In eyes having undergone vitrectomy or combination 210 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 9 vitrectomy and le nsectomy the average clearance rate was 17 days and 7 days, 211 
respectively.18 It was found that the ophthalmoscopic disappearance of injected 212 
triamcinolone acetonide correlated well with a spectrophotometric analysis for clearance of 213 
the drug.  Scholes et al also studied the clearance of intravitreally injected triamcinolone 214 
acetonide (0.4 mg) in 24 rabbit eyes.19 Using high -performance liquid chromatography 215 
(HPLC) complete clearance of the drug was noted by 21 days.  Non- detectable drug levels 216 
(by HPLC) were  present before ophthalmoscopic disappearance. 217 
 218 
As discussed above, corticosteroids have been experimentally shown to downregulate 219 
VEGF production and possibly reduce breakdown of the blood- retinal barrier.15,16  220 
Similarly, steroids have antiangiogenic pro perties possibly due to attenuation of the effects 221 
of VEGF.20,21  These properties of steroids are commonly utilized.  Clinically, 222 
triamcinolone acetonide is used locally as a periocular injection for the treatment of cystoid 223 
macular edema (CME) secondary to uveitis or as a result of intraocular surgery.22,23  In 224 
animal studies, intravitreal triamcinolone acetonide has been used in the prevention of 225 
proliferative vitreoretinopathy24,25 and retinal neovascularization.26,27  Intravitreal 226 
triamcinolone acetonide has been used clinically in the treatment of proliferative 227 
vitreoretinopathy28 and choroidal neovascularization.29-31 228 
 229 
Recently, intravitreal triamcinolone acetonide has been used clinically in the treatment of 230 
retinal vascular disease.  A case report b y Jonas and Sofker describes a patient with non- 231 
proliferative diabetic retinopathy with a 6 -month history of persistent, diffuse macular 232 
edema despite grid photocoagulation.32 Following one intravitreal injection of 233 
triamcinolone acetonide (20mg) the visual acuity of this patient improved from 20/200 to 234 
20/50 over a 5-month follow-up period.  It was also noted that there was marked regression 235 
of macular edema on clinical examination.  236 
 237 
Martidis et al conducted a pilot study of 16 eyes with macular edema due to diabetic 238 
retinopathy.33,34  All 16 eyes demonstrated persistent macular edema involving the center of 239 
the macula despite each eye receiving two to six sessions of focal/grid laser 240 
photocoagulation.  In 11 eyes with a known time of onset of macular edema , the average 241 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 10 duration of macular edema was 32 months (range, 13 to 68 months) prior to intravitreal 242 
triamcinolone acetonide injection.  The other five eyes were known to have macular edema 243 
for at least 6 months.  All 16 eyes were treated with intravitreal triamcinolone acetonide 244 
injection and the results are summarized in Tables 2a and 2b. 245 
 246 
Baseline central foveal thickness averaged 540 microns for the 16 enrolled eyes when 247 
measured by optical coherence tomography.  For 14 eyes evaluated at 1-month, mean 248 
foveal thickness decreased from 533 microns to 242 microns.  Two eyes did not complete 249 
the 1 -month follow- up examination.  Fourteen eyes evaluated at 3 -months showed a 250 
reduction in mean foveal thickness from 528 microns to 224 microns.  Two eyes did not 251 
complete the 3 -month examination; these were different eyes than those that did not 252 
complete the 1 -month examination.  Eight eyes completing six months of follow-up 253 
showed a reduction in mean foveal thickness from 540 microns to 335 microns.  254 
 255 
Mean Snellen vi sual acuity improved by 2.4, 2.4, and 1.3 lines at the 1, 3, and 6-month 256 
follow-up intervals, respectively.  No eyes lost vision at 1-month and all but one eye 257 
showed improvement ranging from one to five lines; nine of 14 (64%) eyes showed 258 
improvement of t wo or more lines at this interval.  No eyes lost vision from baseline at 3 - 259 
months, and all but one eye showed improvement ranging from one to five lines; nine of 14 260 
(64%) eyes showed improvement of two or more lines at the 3-month interval.  One eye 261 
lost a  single line from baseline at six months and one eye remained stable; the other six 262 
eyes maintained improved visual acuity ranging from one to three Snellen lines.  Four of 263 
eight (50%) eyes maintained a visual acuity improvement of two or more lines from 264 
baseline at the 6 -month follow-up.   265 
 266 
Five of 14 eyes that were evaluated at the 1 -month follow-up had an IOP that exceeded 21 267 
mmHg.  The IOP in all five eyes was controlled successfully with one topical aqueous 268 
suppressant.  Two of 14 eyes that were evalua ted at the 3 -month follow-up had an IOP that 269 
exceeded 21 mmHg.  The IOP in both eyes was controlled successfully with one topical 270 
aqueous suppressant.  One of eight eyes that were evaluated at the 6 -month follow-up had 271 
an IOP that exceeded 21 mmHg.  The IO P in this eye was controlled successfully with one 272 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 11 topical aqueous suppressant.  The average IOP increased 45%, 20% and 13% from baseline 273 
at the 1, 3 and 6-month follow-up intervals, respectively.  274 
 275 
Three of the eight eyes completing at least 6 months of follow- up were re-injected 6 months 276 
after initial injection due to recurrence of macular edema.  Cataract progression that did not 277 
require surgery was noted in one eye at the 6 -month follow-up.  No complications such as 278 
retinal detachment, endophthalmitis o r vitreous hemorrhage were noted in this study.  279 
 280 
Greenberg and Martidis studied both eyes of one patient with bilateral diffuse macular 281 
edema secondary to CRVO.35 The right eye of this 80 year old patient had macular edema 282 
from a CRVO of 9 months duration when the patient presented with a 2-week history of 283 
visual acuity loss due to macular edema from a CRVO in the left eye.  Because of the poor 284 
natural history of untreated macular edema in the right eye of this patient, the left eye 285 
received an intravitreal injection of triamcinolone acetonide.  It did well both anatomically 286 
and functionally, with visual acuity improvement from 20/400 to 20/30 after three months 287 
of follow-up.  Central foveal thickness as measured by optical coherence tomography 288 
decreased fr om 589 microns to 160 microns with restoration of a normal foveal contour 289 
following treatment.  Six months following injection, visual acuity decreased to 20/400 290 
because of recurrence of retinal thickening that measured 834 microns by optical coherence 291 
tomography. A second injection was performed and, 1 month later, visual acuity returned to 292 
20/50 with a decrease in central foveal thickness to 158 microns with a normal foveal 293 
contour.  This patient has maintained this level of visual acuity for over 6 months following 294 
the second injection.  Given the response to treatment in the left eye, the right eye (now 295 
with 16 months of untreated macular edema) was treated with an intravitreal injection of 296 
triamcinolone acetonide.  There was a prompt reduction in centra l foveal thickness as 297 
measured by optical coherence tomography from 735 microns to 195 microns.  However, 298 
possibly as a result of the duration of macular edema, no visual benefit was noted.  No 299 
significant elevation of IOP was noted in either eye.   300 
 301 
Other  clinical case reports by Ip et al and Jonas et al have demonstrated similar results in 302 
the treatment of macular edema due to CRVO with intravitreal injections of triamcinolone 303 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 12 acetonide.36,37  Recently, Park et al evaluated intravitreal triamcinolone inje ction(s) as a 304 
treatment of macular edema associated with CRVO.38  Ten eyes of 9 patients with perfused 305 
CRVO with visual acuity 20/50 or worse were treated with an intravitreal injection of 306 
triamcinolone acetonide (4mg/0.1cc).  One patient received a repeat  injection.  The mean 307 
duration from time of diagnosis to the intravitreal triamcinolone injection was 15.4 months. 308 
The mean best -corrected visual acuity improved from 58 letters (range, 37- 72) at baseline 309 
to 78 letters (range 50- 100 letters) at last follow -up (mean, 4.8 months).  Volumetric optical 310 
coherence tomography (VOCT) was performed on 9 of 10 patients at baseline and follow- 311 
up.  VOCT measurements improved from a mean of 4.2 mm3 at baseline to a mean of 2.6 312 
mm3 at last follow -up (normal range of VOCT is 2.0-2.5 mm3).  Three eyes without a 313 
previous history of glaucoma required topical antiglaucoma medication.  One eye with a 314 
previous history of open- angle glaucoma required trabeculectomy surgery.  315 
 316 
Table 3 lists the frequency and nature of adverse effects seen in some of the largest clinical 317 
studies thus far using intravitreal triamcinolone acetonide.  Penfold and Challa studied 30 318 
eyes with exudative macular degeneration.29,30  No adverse events such as retinal 319 
detachment, vitreous hemorrhage or endophthalmitis were noted.  However, three of four 320 
eyes that received a second injection of triamcinolone acetonide experienced rapid 321 
progression of cataract within 2 months of re-injection.  Two of these four eyes also 322 
experienced steroid -induced glaucoma with IOP elevation to 37 mmHg.  Both eyes had 323 
argon laser trabeculoplasty and were treated with topical aqueous suppressants.  One of 324 
these two eyes required trabeculectomy surgery to control IOP.  In another series, Danis et 325 
al injected 16 eyes with exudative macular degeneration.31 No adverse events such as 326 
retinal detachment, vitreous hemorrhage or endophthalmitis were noted.  Four of seven 327 
phakic patients developed progressive lens opacities that over the 6-month follow-up did 328 
not require cataract surgery.  Four patients developed transient IOP elevation that required 329 
one to two topical aqueous suppressants to lower the intraocular pressure to less than 25 330 
mmHg; all patients eventually had topical therapy discontinued.  No patient had IOP over 331 
32 mmHg at any point in follow-up. 332 
 333 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 13 The other studies listed in Table 3 all demonstrate a similar adverse event profile.28,39-41  A 334 
summary of the data from the seven studies listed shows that the frequency of injection- 335 
related adverse events such as endophthalmitis, non- infectious endophthalmitis, retinal 336 
detachment and vitreous hemorrhage appear rare based on these small studies in the 337 
published literature.  Corticosteroid- related adverse events, from the data in Table 3, are 338 
more common.  However, corticosteroid- related adverse events (cataract and elevated IOP) 339 
appear to be manageable.  For example, of the 221 patients in the seven studies discussed, 340 
33 patients (15%) were noted to have some elevation of IOP; all patients were managed 341 
successfully with topical aqueous suppressants except one patient who required argon laser 342 
trabeculoplasty and one patient who required both argon laser trabeculoplasty and 343 
trabeculectomy.  Nine patients (4%) required cataract surgery and 24 patients (12%) were 344 
noted to have progressive lens opacity. 345 
346 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0 CONFIDENTIAL  Page 14 Table 2a: Clinical characteristics of sixteen patients treated with intravitreal 347 
triamcinolone injection for diabetic macular edema not responsive to 348 
focal/grid photocoagulation 349 
 350 
Case  Eye Age Lens  Retinopathy  Duration 
ME (mo)  Prior 
Laser  
1 OS 72 Pseudo  NPDR  21 2 
2 OD 48 Phakic  PDR  36 2 
3 OS 85 Phakic  NPDR  29 3 
4 OS 76 Phakic  NPDR  13 2 
5 OS 70 Pseudo  NPDR  23 3 
6 OD 68 Phakic  NPDR  47 5 
7 OD 70 Phakic  PDR  >6 2 
8 OD 59 Phakic  NPDR  >6 2 
9 OS 67 Phakic  NPDR  26 2 
10 OD 52 Phakic  PDR  68 3 
11 OS 71 Pseudo  NPDR  50 6 
12 OS 74 Phakic  NPDR  12 2 
13 OS 62 Phakic  NPDR  >6 2 
14 OS 65 Phakic  NPDR  24 2 
15 OD 43 Phakic  NPDR  >6 2 
16 OD 62 Phakic  NPDR  >6 2 
 351 
Table 2b: Clinical characteristics of sixteen patients treated with intravitreal 352 
triamcinolone injection for diabetic macular edema not responsive to 353 
focal/grid photocoagulation 354 
 355 
Visual Acuity   OCT (microns)   IOP (mmHg)   F/U Reinject  
Initial  1 mo  3 mo  6 mo   Initial  1 mo  3 mo  6 mo   Initial  1 mo  3 mo  6 mo   (mo)  (mo)  
20/400  20/200  20/200  20/200   612 378 214 236  14 24 18 16  12 No 
20/80  20/50  20/60  20/100   569 171 132 519  16 20 18 16  11 11 
20/200  20/60  20/60  20/60   550 177 181 208  18 12 14 20  11 No 
20/400  20/200  20/100  20/100   401 232 199 174  17 22 33 16  10 No 
20/400  20/200   20/400   557 154  621  15 28  14  9 6 
20/200   20/80  20/100   583  109 90  15  17 23  8 No 
20/400  20/60   20/100   703 264  588  14 21  16  7 6 
20/60  20/30  20/30  20/40   348 268 270 242  10 17 13 13  6 No 
20/800  20/100  20/100    564 397 360   17 17 22   5 No 
20/80  20/60  20/60   585 199 188   15 18 15   4 No 
20/200  20/200  20/100    510 260 265   12 17 11   3 No 
20/400   20/400    596  233   14  14   3 No 
20/200  20/60  20/40    497 213 180   12 30 16   3 No 
20/200  20/60  20/60    497 239 424   15 16 20   3 No 
20/200  20/40  20/40  20/40   674 262 204   17 20 16   3 No 
20/100  20/50  20/40    399 180 176   14 36 20   3 No 
 356 
NPDR:  non-proliferative diabetic retinopathy  357 
PDR:  proliferative diabetic retinopathy  358 
ME:  macular edema 359 
Pseudo:  pseudophakic  360 
OCT:  optical coherence tomography  361 
IOP:  intraocular pressure 362 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008 
 
 
 
Version 7.0  CONFIDENTIAL  Page 15  Table 3: Summary of adverse events from seven case series using intravitreal triamcinolone acetonide  363 
 364 
  
# Eyes treated   
Disease  
Dose 
(mg)   
IOP rise  
  
Cataract  
(surgery)   
Lens  
Opacity   
R.D.   
Vit 
Heme   
Endophth  
Non-infectious 
endophthalmitis  
Wingate39 113 AMD  4 12 NA NA NA NA NA NA 
Penfold29 30 AMD  4 3 9 1 0 0 0 0 
Danis31 16 AMD  4 4 0 4/7 
phakic  0 0 0 0 
Jonas28 16 PVR  10-20 0 0 0 0 0 0 1 
Martidis33 16 DME 4 5 0 1 0 0 0 0 
Jonas40 4 NVG  20 0 0 0 0 0 0 0 
Jonas41 26 DME 25 9 0 18/18 phakic 
(P=.16)  0 0 0 0 
7 Studies 
(pooled)  221  
  
 33 (15%)  9 (4%)  24 (12%)  0 0 0 1 
 365 
AMD  Age-related macular degeneration  366 
DME Diabetic macular edema 367 
PVR  Proliferative vitreoretinopathy  368 
NVG Neovascular glaucoma 369 
RD Retinal detachment  370 
NA Not available; these adverse events were not specifically discussed in the manuscript  371 
 372 
 373 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 16 2.4 Other Studies Evaluating Corticosteroid Preparations Other Than 374 
Triamcinolone Acetonide for Treatment of Macular Edema due to Retinal 375 
Vascular Disease 376 
2.4.1 Efficacy  377 
2.4.1.1 Control Delivery Systems ( Bausch and Lomb)  378 
Control Delivery Systems (Bausch and Lomb) is developing a non- 379 
biodegradable, implantable, extended release product that delivers the 380 
corticosteroid fluocinolone acetonide directly to the posterior segment of the 381 
eye for a period of 3 year s.  A multi-center, randomized, masked trial is 382 
currently being conducted to evaluate this technology for the treatment of 383 
diabetic macular edema refractory to prior laser photocoagulation.  Eligible 384 
visual acuity was between 20/50 to 20/400, inclusive.  This trial enrolled 80 385 
patients with diabetic macular edema.  Patients were randomly assigned to one 386 
of three treatment arms:  0.5 mg implant (N=41), 2 mg implant (N=11) or 387 
standard of care treatment consisting of either repeat laser photocoagulation or 388 
observation (N=28).  (The 6-month data shown below were presented at the 389 
combined Vitreous Society and Retina Society Meeting, San Francisco, CA on 390 
September 30, 2002.  The 12- month data presented below were presented at 391 
the Association for Research in Vision and Ophthalmology Meeting, Ft. 392 
Lauderdale, FL on May 8, 2003).  393 
• At the 6 -month follow-up, the proportion of eyes with maintained or 394 
improved visual acuity was greater in eyes that received the 0.5 mg 395 
implant than those assigned to standard of care treatment (P<0.01).  396 
This result was not statistically significant at the 12 -month follow-up. 397 
• At the 6 -month follow-up, the proportion of eyes with a two or more 398 
step decrease in retinal thickening at the center of the fovea was greater 399 
in eyes that received the 0.5 mg implant than those assigned to 400 
standard of care treatment (P=0.026).  This result remained statistically 401 
significant at the 12 -month follow-up (P=0.003). 402 
 403 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 17 2.4.1.2 Oculex  404 
Oculex is developing a biodegradable, implantable, extended release product 405 
(Posurdex) that delivers the corticosteroid dexamethasone directly to the 406 
posterior segment of the eye for a period of 35 days.  A phase two clinical trial 407 
was completed evaluating two dosages of Posurdex, 350 micrograms and 700 408 
micrograms.  Patients with macular ede ma due to diabetic retinopathy, retinal 409 
vascular occlusive disease, Irvine-Gass syndrome or uveitis were included.  410 
Eligible visual acuity was 20/40 -20/200.  Patients were randomized to one of 411 
three treatment arms:  350 microgram implant, 700 microgram imp lant or 412 
observation.  306 patients were enrolled, 172 with diabetic macular edema, 413 
103 with vein occlusion, 27 with Irvine-Gass syndrome and 14 with uveitic 414 
macular edema.  415 
• Patients receiving the 700 microgram implant had a statistically 416 
significant improve ment in visual acuity of two or more lines on the 417 
ETDRS chart when compared to patients who did not receive the 418 
implant (P=0.019). 419 
• Secondary outcomes such as retinal thickness and fluorescein leakage 420 
also showed statistically significant decreases in patie nts that received 421 
the 700 microgram implant when compared to patients who did not 422 
receive the implant (P=0.001). 423 
• Patients receiving the 350 microgram implant also demonstrated 424 
statistically significant decreases in retinal thickness and fluorescein 425 
leakage, with a trend towards improvement in visual acuity, indicating 426 
a dose response to the treatment.  427 
 428 
2.4.2 Adverse Effects  429 
2.4.2.1 Control Delivery Systems (Bausch and Lomb) 430 
Elevated IOP  431 
• At the 6 -month follow-up, 12.2% of patients in the 0.5 mg implant 432 
group had an IOP elevation to 30 mmHg or more.  All patients were 433 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 18 managed with topical antiglaucoma medication.  No eye in the 434 
standard of care group had such an elevation in IOP. 435 
• At the 12-month follow-up, 19.5% of patients in the 0.5 mg implant 436 
group had an IOP elevation t hat was considered a serious adverse 437 
event. Three patients in the 0.5 mg implant group required 438 
trabeculectomy surgery.  No eye in the standard of care group had such 439 
an elevation in IOP. 440 
Cataract  441 
• At the 6 -month follow-up, 0.0% of patients in the standard of care 442 
group had “cataract progression”.  Seventeen percent of patients in the 443 
0.5 mg group had “cataract progression. 444 
• At the 12-month follow-up, 0.0% of patients in the standard care group 445 
had cataract progression defined as a serious adverse event.  For ty-one 446 
percent of patients in the 0.5 mg group (all study eyes) had cataract 447 
progression defined as a serious adverse event. 448 
 449 
2.4.2.2 Oculex  450 
Elevated IOP  451 
• An IOP elevation to 25 mmHg or more was noted at some point in 452 
the study in 32 eyes; all were readily controll ed with topical 453 
antiglaucoma medication.  454 
Cataract and other side effects  455 
• There was no difference in cataract progression between the study 456 
groups. 457 
• No other safety concerns were noted.  458 
 459 
2.5 Rationale for the Intravitreal Triamcinolone Acetonide Doses to be Eval uated  460 
The optimal dose of triamcinolone acetonide to maximize efficacy with minimum side 461 
effects is not known.  A 4 mg dose of Kenalog, a commercially available preparation that is 462 
FDA labeled for intramuscular or intrabursal use, is principally being used in clinical 463 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 19 practice.  However, this dose has been used based on feasibility rather than scientific 464 
principles. 465 
 466 
There is also experience using doses of 1 mg and 2 mg.  These doses anectodally have been 467 
reported to reduce macular edema.  There is a ration ale for using a dose lower than 4 468 
mg.42,43  Glucocorticoids bind to glucocorticoid receptors in the cell cytoplasm, and the 469 
steroid -receptor complex moves to the nucleus where it regulates gene exp ression. The 470 
steroid -receptor binding occurs with high affinity (low dissociation constant (Kd) which is 471 
on the order of 5 to 9 nanomolar).  Complete saturation of all the receptors occurs at about 472 
20 fold higher levels, so about 100 nanomolar.  A 4 mg dose of triamcinolone/4mg of 473 
vitreous volume yields a final concentration of 7.5 millimolar, or nearly 10,000 fold more 474 
than the saturation dose. Thus, the effect of a 1 mg dose may be equivalent to that of a 4mg 475 
dose, because compared to the 10,000 fold saturation, a 4-fold difference in dose is 476 
inconsequential.  It is also possible that higher doses of corticosteroid could be less 477 
effective than lower doses due to down-regulation of the receptor.  The steroid implant 478 
studies provide additional justification for evaluating a lower dose—a 0.5 mg device which 479 
delivers only 0.5 micrograms per day has been observed to have a rapid effect in reducing 480 
macular edema (P. Andrew Pearson, personal communication). 481 
 482 
There has been limited experience using doses greater than 4 mg.  Jonas’ case series 483 
described earlier reported results using both a 20mg and a 25mg dose.  However, others 484 
have not been able to replicate this dose using the preparation procedure described by Jonas 485 
(Frederick Ferris, personal communication).   486 
 487 
In the SCORE Study, 4 mg and 1 mg doses will be evaluated.  The former because it is the 488 
dose that is currently most commonly used in clinical practice and the latter because there is 489 
reasonable evidence for efficacy and the potential for lower risk.  Alth ough there is good 490 
reason to believe that a 1 mg dose will reduce macular edema, it is possible that the 491 
retreatment rate will be higher with this dose compared with 4 mg since the latter will 492 
remain active in the eye for a longer duration than the former.  Insufficient data are 493 
available to warrant evaluating a dose higher than 4mg at this time.   494 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 20  495 
2.6 Mechanism of Adverse Effects Associated with Intravitreal Steroids  496 
2.6.1 Elevation of Intraocular Pressure 497 
IOP depends on the comparative rates of aqueous production and aqueous drainage, 498 
primarily through the trabecular meshwork.  Increased IOP occurs from a variety of 499 
mechanisms such as primary or secondary angle-closure glaucoma, primary or 500 
secondary open-angle glaucoma, or combined- mechanism glaucoma.  If inadequately 501 
treated, increased IOP may result in glaucomatous optic nerve changes and loss of 502 
visual field.  503 
 504 
Among the secondary open- angle glaucomas, corticosteroid -induced elevation of IOP 505 
is one of the most common.  This relationship is well established.  In pat ients 506 
susceptible to this phenomenon, the elevation of IOP may occur as a result of topical, 507 
systemic or peribulbar administration.  For example, following 4-6 weeks of topical 508 
corticosteroid administration, 5% of subjects may show an elevation in IOP of 509 
>16mmHg and 30% of subjects may show an elevation of 6-15mmHg.44,45 510 
 511 
The mechanism of corticosteroid induced elevation of IOP is incompletely 512 
understood. Possible theories include46:  a) inhibition of the production of outflow- 513 
enhancing prostaglandins,  b) suppression of trabecular meshwork endothelial cell 514 
phagocytosis,  c) increased deposition of proteoglycans or glycosaminoglycans in the 515 
trabecular meshwork with a resultant increase in resistance to outflow,  d) increase in 516 
cross -linked actin networks in the trabecular meshwork,  e) increase in the expression 517 
of cellular tight-junction protein,  f) stabilization of lysosomes which allow 518 
accumulation of hyaluronate or other debris in the trabecular meshwork. 519 
 520 
The intravitreal administration of corticosteroid is expected to be associated with an 521 
increase in IOP in susceptible patients.  Indeed, the literature reviewed in this protocol 522 
confirm that corticosteroid induced elevation in IOP may result from intravitreal 523 
corticosteroid administration (Table 3).  The time course for the development of 524 
corticosteroid induced elevation in IOP as a result of intravitreal injection is presently 525 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 21 unknown.  Additionally, the effect of the initial dose administered, the frequency of 526 
reinjection or the cumulative dose administered over time on the severity of IOP 527 
elevation is not known.  The experience thus far indicates that the 4 mg and 25 mg 528 
doses of triamcinolone acetonide appear to result in a relatively similar frequency and 529 
severity of IOP elevation 33,41 Reinjection of the 4 mg dose at a frequency of more 530 
than once every four months appears to be associated with more frequent and more 531 
severe elevation in IOP.29 532 
 533 
All patients who receive intravitreal injection of corticosteroid will have IOP 534 
monitored carefully in this s tudy.  The frequency and severity of IOP elevation will be 535 
monitored. 536 
 537 
2.6.2 Cataract Formation 538 
An opacity of the lens that results in loss of transparency and/or causes light scatter is 539 
called a cataract.  The reasons why cataracts occur include:  formation of opaque 540 
fibers, fibrous metaplasia, epithelial opacification, accumulation of pigment and 541 
formation of extracellular materials.  These changes can occur as a result of the aging 542 
process, trauma, radiation, electric shock, in association with systemic disorders, or as 543 
a result of drugs or chemicals.  The most common types of cataract are cortical, 544 
nuclear and posterior subcapsular.47 In cortical cataracts, the soluble protein content 545 
decreases and results in lens alteration.  Nuclear cataracts may form as a r esult of an 546 
increase in insoluble protein content along with the accumulation of chromophores.  547 
Posterior subcapsular cataracts are caused by dysplastic changes in germinal 548 
epithelium.  These dysplastic cells migrate posteriorly and give rise to bladder cells of 549 
Wedl, resulting in posterior subcapsular opacity. 550 
 551 
Among the toxic causes of cataract, corticosteroid -induced cataract is one of the most 552 
common.  The relationship between dose and duration of exposure to the formation of 553 
cataract is unclear.  However, the association between corticosteroids and cataract is 554 
well established.  Corticosteroid induced cataracts typically show an axial, posterior 555 
subcapsular opacity which gradually increases in size.  Topical, systemic and 556 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 22 peribulbar corticosteroid administration have all been associated with an increased 557 
risk of cataract formation.48 Even the prolonged administration of inhaled 558 
corticosteroids has been associated with an increased risk of cataract formation.49 559 
 560 
The intravitreal administration of corticos teroid is also expected to be associated with 561 
cataract formation.  Indeed, the literature reviewed in this protocol confirms that 562 
cataracts appear to result from intravitreal corticosteroid administration (Table 3).  563 
The time course for the development of cataract as a result of intravitreal 564 
corticosteroid injection is presently unknown.  However, it is believed that the 565 
formation of cataract in response to intravitreal administration is gradual and takes 566 
place over the course of approximately 1 year.  As w ith other routes of corticosteroid 567 
administration, posterior subcapsular cataract appears to be the most common type of 568 
cataract to form following the intravitreal administration of corticosteroid.  Table 3 569 
shows that 4% of patients in the 7 pooled studies required cataract surgery and 12% 570 
had progressive lens opacity.  These studies had at least 3 months of follow-up and, in 571 
some cases, substantially more.  572 
 573 
Corticosteroid induced cataract will be followed closely as an adverse event in this 574 
study. 575 
 576 
2.6.3 Endopht halmitis  577 
Infectious endophthalmitis is an intraocular inflammatory process due to infection 578 
with pathogens such as bacteria or fungi.  Clinical features include lid edema, 579 
conjunctival injection, corneal edema, anterior chamber and vitreous inflammation, 580 
and hypopyon.  Infectious endophthalmitis can occur following an intraocular 581 
procedure (e.g. cataract surgery, vitrectomy surgery, intravitreal injection), as a result 582 
of systemic infection, as a result of trauma, or occur as a late feature of conjunctival 583 
filtering blebs.  584 
 585 
Acute postoperative endophthalmitis following cataract surgery is the most common 586 
cause. The overall incidence, however, is low and in one survey the incidence 587 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 23 following cataract surgery was <1%.50 In the Endophthalmitis Vitrectomy Study 588 
(EVS), gram -positive organisms accounted for 94% of culture positive cases.51 589 
 590 
The incidence and causative pathogens following intravitreal injection of 591 
corticosteroid are less well defined.  In the published literature, this complication 592 
appears uncommon (Table 3).  Endophthalmitis following intravitreal injection of 593 
antiviral agents for the treatment of CMV retinitis also appears to be uncommon 594 
(personal communication, Daniel F. Martin).  However, the injection of a bolus of 595 
medication that has immunosuppressive properties may result in a higher incidence of 596 
postinjection endophthalmitis using corticosteroids.  A standardized protocol to 597 
prepare eyes for the injection procedure may help to decrease the incidence of this 598 
complication.  Such a protocol is described in the Manual of Procedures and 599 
Procedures (MOPP).  600 
 601 
The clinical experience to date has been with the use of Kenalog.  Kenalog is a 602 
commercially available preparation that is FDA labeled for intramuscular or 603 
intrabursal use.  The available preparat ion of Kenalog contains, in addition to 604 
triamcinolone acetonide, 0.99% benzyl alcohol, 0.75% carboxymethylcellulose 605 
sodium and 0.04% polysorbate 80.52 Although the published literature to date does 606 
not describe a significant incidence of complications as a result of the Kenalog 607 
vehicle, anecdotal experience suggests that there may be a significant incidence of 608 
non-infectious endophthalmitis as a result of the vehicle components [American 609 
Society of Retinal Specialists listserve from 2002 -2003].  As a result of the possibility 610 
of a sterile reaction to the components of the Kenalog vehicle, it is difficult to be 611 
certain if an inflammatory reaction is infectious or non -infectious following an 612 
injection of Kenalog.  Treatment of infectious endophthalmitis requir es immediate 613 
treatment with intravitreal antibiotics with or without vitrectomy surgery depending 614 
on the clinical situation.  Non- infectious endophthalmitis is usually self -limiting.  A 615 
sterile, preservative-free triamcinolone preparation will be used in this study. 616 
 617 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 24 Despite the use of a sterile, preservative- free preparation, inflammatory reactions 618 
following intravitreal injection as well as the frequency of infectious endophthalmitis 619 
will be monitored carefully in this study.  620 
 621 
3. Objectives  622 
The primary objective of the SCORE Study is to compare visual acuity outcome among 3 groups 623 
of participants: those who are randomly assigned to receive standard care and those randomly 624 
assigned to receive one of two doses of intravitreal injection(s) of triamcinolone acetonide for 625 
treatment of macular edema associated with CRVO and BRVO.  Secondary objectives include 626 
estimating the incidence of infectious endophthalmitis, non- infectious endophthalmitis, retinal 627 
detachment, vitreous hemorrhage, cataract and elevated IOP in eyes receiving intravitreal 628 
injection(s) of triamcinolone.  Other secondary objectives include comparing changes in retinal 629 
thickness and calculated retinal thickening in participants who are randomly assigned to receive 630 
intravitreal injection(s) of triamcinolone acetonide with those randomly assigned to standard care 631 
for treatment of macular edema associated with CRVO and BRVO.  632 
 633 
4. Study Design and Methods  634 
The SCORE Study is a multicenter, randomized, Phase III trial designed to compare the efficacy 635 
and safety  of standard care with intravitreal injection(s) of triamcinolone acetonide for the 636 
treatment of macular edema associated with CRVO and BRVO.  Eligible participants within each 637 
of these two disease entities will be randomized in a 1:1:1 ratio to one of thr ee groups (treatment 638 
of neovascular complications as necessary in all three groups):   639 
1. Standard care group: conventional treatment consisting of: 640 
a. CRVO:  641 
i. Observation of macular edema.  642 
b. BRVO:  643 
i. Study eyes with dense macular hemorrhage:  Immediate observation.  G rid 644 
laser photocoagulation will be performed if and when clearance of hemorrhage 645 
permits grid laser photocoagulation. 646 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 25 ii. Study eyes without dense macular hemorrhage:  Immediate grid laser 647 
photocoagulation. 648 
   or 649 
2. Intravitreal injection(s) of 4 mg of triamcinolone acetonide,  650 
   or 651 
3. Intravitreal injection(s) of 1 mg of triamcinolone acetonide.  652 
 653 
Note:  Patients and investigators will be masked to the triamcinolone acetonide dose used (1 654 
mg or 4 mg).  655 
 656 
4.1 Efficacy Assessment  657 
4.1.1 Primary Efficacy Outcome 658 
The primary efficacy  outcome of this study is improvement by 15 or more letters from 659 
baseline in best -corrected ETDRS visual acuity score at the 12 -month visit as 660 
determined by the ETDRS visual acuity protocol.  The primary outcome analysis will 661 
include the following three comparisons of the proportion of participants having a 15 662 
ETDRS letter improvement from baseline to 1 year: 663 
• 4 mg triamcinolone acetonide intravitreal injections with standard care  664 
• 1 mg triamcinolone acetonide intravitreal injections with standard care  665 
• 4 mg triamcinolone acetonide intravitreal injections with 1 mg triamcinolone 666 
acetonide intravitreal injections  667 
 668 
4.1.2 Secondary Efficacy Outcomes  669 
Secondary efficacy outcomes include the following: 670 
• Change between baseline and each efficacy outcome assessment visit in  671 
best-corrected ETDRS visual acuity score (e.g., mean change from baseline 672 
in visual acuity, distribution of change from baseline in visual acuity based 673 
on clinically meaningful cut points of improvement or worsening of visual 674 
acuity).  675 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 26 • Change in calculated  retinal thickening as assessed by optical coherence 676 
tomography. 677 
• Change in retinal thickness at the center of the macula as assessed by 678 
stereoscopic color fundus photography. 679 
• Change in area of retinal thickening as assessed by stereoscopic color fundus 680 
photography. 681 
 682 
4.2 Safety Assessments 683 
4.2.1 Safety Outcomes  684 
Safety outcomes will be tabulated by observing the nature, severity and frequency of 685 
adverse events throughout the three years of the study.  Specific safety outcomes 686 
include: 687 
• Injection -related events including infectious endophthalmitis, non-infectious 688 
endophthalmitis, retinal tear or detachment, vitreous hemorrhage, ocular 689 
discomfort/irritation, ocular tenderness, ocular itching sensation, foreign 690 
body sensation, blurred vision, floaters, corneal abrasion, subconjunctival 691 
hemorrhage, conjunctival edema, and conjunctival hyperemia/erythema. 692 
• Steroid -related toxicities including cataract and elevated IOP.  693 
 694 
4.3 Inclusion Criteria  695 
4.3.1 General Inclusion Criteria  696 
a. Ability and willingness to provide informed consent. 697 
b. Sex:  Participants may be male or female.  698 
c. Age: 18 years or older 699 
 700 
4.3.2 Ocular Inclusion Criteria (study eye)  701 
a. Participants must have center -involved macular edema secondary to 702 
either CRVO or BRVO.  Eyes may be enrolled as early as the time 703 
diagnosis of the macular edema, but not longer than 24 months after 704 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 27 diagnosis (by patient history or ophthalmologic diagnosis).  The 705 
following definitions are used for the purposes of the SCORE Study: 706 
i. A CRVO is defined as an eye that has retinal hemorrhage or other 707 
biomicroscopic evidence of retinal vein occlusion (e.g. 708 
telangiectatic capillary bed) and a dilated venous system (or 709 
previously dilated venous system) in all 4 quadrants. 710 
ii. A BRVO is defined as an eye that has retinal hemorrhage or other 711 
biomicroscopic evidence of retinal vein occlusion (e.g. 712 
telangiectatic capillary bed) and a dilated venous system (or 713 
previously dilated venous system) in 1 quadrant or less of retina 714 
drained by the affected vein.  715 
iii. A hemiretinal vein occlusion (HRVO) is defined as an eye that 716 
has retinal hemorrhag e or other biomicroscopic evidence of retinal 717 
vein occlusion (e.g. telangiectatic capillary bed) and a dilated 718 
venous system (or previously dilated venous system) in more than 719 
1 quadrant but less than all 4 quadrants.  Typically, a HRVO is a 720 
retinal vein o cclusion that involves 2 altitudinal quadrants.  For 721 
the purposes of the SCORE Study, eyes with HRVO will be treated 722 
as eyes with BRVO and analyzed with the BRVO group. 723 
b. ETDRS visual acuity score of greater than or equal to 19 letters 724 
(approximately 20/400) and less than or equal to 73 letters 725 
(approximately 20/40) by the ETDRS visual acuity protocol.  726 
• Note: There will be an enrollment limit of 15% of eyes with visual 727 
acuity between 19 and 33 letters.  The investigator must believe that 728 
a study eye with visual acuity between 19 and 33 letters is perfused. 729 
c. Mean retinal thickness on two OCT measurements greater than or equal 730 
to 250 microns (central subfield). 731 
d. Media clarity, pupillary dilation and participant cooperation sufficient 732 
for adequate fundus photographs.  733 
 734 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 28 4.4 Exclusion Criteria  735 
4.4.1 General Exclusion Criteria  736 
Participants with any of the following conditions are ineligible: 737 
a. A condition that, in the opinion of the investigator, would preclude 738 
participation in the study (e.g., chronic alcoholism or drug abuse, 739 
personality disorder or use of major tranquilizers indicating difficulty in 740 
long term follow -up, likelihood of survival of less than 3 years). 741 
b. Participation in an investigational trial within 30 days of study entry that 742 
involved treatment with any drug that has not received regulatory approval 743 
at time of study entry.  744 
c. History of allergy to any corticosteroid or component of the delivery 745 
vehicle.  746 
d. Sitting systolic blood pressure greater than 180 mmHg or diastolic blood 747 
pressure greater than 110 mmHg.  If the init ial reading exceeds these 748 
values, a second reading may be taken two or more hours later; the patient 749 
may be included (if all other inclusion criteria are met) in the study if the 750 
second reading demonstrates a systolic blood pressure equal to or less than 751 
180 mmHg and the diastolic blood pressure is 110 mmHg or less.  If the 752 
blood pressure is brought to 180 mmHg systolic or less and 110 mmHg 753 
diastolic or less by antihypertensive treatment, the patient can become 754 
eligible.  755 
e. The participant will be moving out of the area of the clinical center to an 756 
area not covered by another clinical center during the 3 years of the study. 757 
f. History of systemic (e.g., oral, IV, IM, epidural, bursal) corticosteroids 758 
within 4 months prior to randomization or corticosteroid eyedrops in 759 
current use more than 2 times per week.  760 
• Note:  Patients taking topical, rectal or inhaled corticosteroids are 761 
eligible for the study.  762 
g. Positive urine pregnancy test: all women of childbearing potential (those 763 
who are pre-menopausal and not surgically s terilized) may participate only 764 
if they have a negative urine pregnancy test, if they do not intend to 765 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 29 become pregnant during the timeframe of the study and if they agree to use 766 
at least one of the following birth control methods: hormonal therapy such 767 
as oral, implantable or injectable chemical contraceptives; mechanical 768 
therapy such as spermicide in conjunction with a barrier such as a condom 769 
or diaphragm; intrauterine device (IUD); or surgical sterilization of 770 
partner.  771 
 772 
4.4.2 Ocular Exclusion Criteria (study eye)  773 
a. Exam evidence of vitreoretinal interface disease (e.g. vitreomacular 774 
traction, epiretinal membrane), either on clinical examination or optical 775 
coherence tomography thought to be contributing to macular edema. 776 
b. An eye that, in the investigator’s opinion, would not benefit from 777 
resolution of macular edema such as eyes with foveal atrophy, dense 778 
pigmentary changes or dense subfoveal hard exudates. 779 
c. Presence of an ocular condition that, in the opinion of the investigator, 780 
might affect macular edema or alter v isual acuity during the course of the 781 
study (e.g., age- related macular degeneration, uveitis or other ocular 782 
inflammatory disease, neovascular glaucoma, Irvine-Gass Syndrome, prior 783 
macula-off rhegmatogenous retinal detachment). 784 
d. Presence of a substantial cataract that, in the opinion of the investigator, is 785 
likely to be decreasing visual acuity by 3 lines or more (i.e. a 20/40 786 
cataract).  787 
e. History of laser photocoagulation for macular edema within 4 months 788 
prior to randomization. 789 
• Note:  If prior grid laser photocoagulation has been performed, the 790 
study eye must have either:  791 
a. One or more disc areas of leakage on the fluorescein angiogram 792 
(FA).  This area of leakage must be contiguous with the fovea 793 
and have no evidence of prior laser treatment. 794 
OR 795 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 30 b. Two or more dis c areas of leakage on the fluorescein angiogram 796 
(FA).  This area of leakage must be contiguous with the fovea 797 
and have evidence of clearly inadequate prior laser treatment.  798 
f. History of intravitreal corticosteroid injection.  799 
g. History of peribulbar or retrobulbar corticosteroid use for any reason 800 
within 6 months prior to randomization. 801 
h. History of panretinal scatter photocoagulation (PRP) or sector laser 802 
photocoagulation within four months prior to randomization or anticipated 803 
within the next four months following randomization. 804 
i. History of pars plana vitrectomy. 805 
j. History of major ocular surgery (including cataract extraction, scleral 806 
buckle, any intraocular surgery, etc.) within 6 months prior to 807 
randomization or anticipated within the next 6 months following 808 
randomization.  809 
k. History of YAG capsulotomy performed within 2 months prior to 810 
randomization. 811 
l. IOP greater than or equal to 25 mm Hg.  812 
m. Exam evidence of pseudoexfoliation. 813 
n. History of steroid -induced IOP elevation that required IOP-lowering 814 
treatment.  815 
o. History of open angle glaucoma (either primary open angle glaucoma or 816 
other cause of open angle glaucoma; note: prior angle closure glaucoma is 817 
not an exclusion). 818 
• A history of ocular hypertension (or IOP greater than or equal to 22 819 
mm Hg without a prior diagnosis of ocular hypertension) is not an 820 
exclusion as long as (1) IOP is less than 25 mm Hg, (2) the patient is 821 
using no more than one topical glaucoma medication, (3) the most 822 
recent visual field, performed within the last 12 months, is normal (if 823 
abnormalities are p resent on the visual field they must be attributable 824 
to the patient’s macular disease), and (4) the optic nerve does not 825 
appear glaucomatous.  826 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 31 • Note:  If IOP is 22 to less than 25 mm Hg, then the above criteria for 827 
ocular hypertension eligibility must be met.  828 
p. History of herpetic ocular infection. 829 
q. History of ocular toxoplasmosis. 830 
r. Aphakia. 831 
s. Exam evidence of external ocular infection, including conjunctivitis, 832 
chalazion or significant blepharitis.  833 
t. History of macular detachment.  834 
u. Exam evidence of any diabetic reti nopathy, defined as eyes of diabetic 835 
patients with more than one microaneurysm outside the area of the vein 836 
occlusion (inclusive of both eyes). 837 
v. History of idiopathic central serous chorioretinopathy. 838 
4.4.3 Fellow (Non- Study) Eye Criteria (the Fellow Eye Must Meet the 839 
Following) 840 
a. ETDRS visual acuity score of greater than or equal to 19 letters 841 
(approximately 20/400) 842 
b. No prior history of intravitreal corticosteroid injection.  843 
c. IOP less than 25 mm Hg. 844 
d. No exam evidence of pseudoexfoliation. 845 
e. No history of steroid-induced IOP elevation that required IOP lowering 846 
treatment.  847 
f. No history of open- angle glaucoma (either primary open -angle glaucoma 848 
or other cause of open- angle glaucoma; note: angle- closure glaucoma is 849 
not an exclusion). 850 
• A history of ocular hypertension (or IOP greater than or equal to 22 851 
mm Hg without a prior diagnosis of ocular hypertension) is not an 852 
exclusion as long as (1) IOP is less than 25 mm Hg, (2) the patient is 853 
using no more than one topical glaucoma medication, (3) the most 854 
recent visual field, performed within the last 12 months, is normal (if 855 
abnormalities are present on the visual field they must be attributable 856 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 32 to the patient’s macular disease), and (4) the optic nerve does not 857 
appear glaucomatous.  858 
• Note:  If the IOP is 22 to less than 25 mm Hg, then the above criteria 859 
for ocular hypertension must be met 860 
4.5 Informed Consent, Screening Evaluation, and Randomization 861 
4.5.1 Informed Consent  862 
Potential participants in the SCORE Study will be assessed as part of routine -care 863 
examinations.  Prior to completing a ny procedures or collecting any data that are not 864 
part of usual medical care, written informed consent will be obtained.  The informed 865 
consent should be reviewed with the patient at this visit and signed with the 866 
understanding that the patient may or may not be eligible.  Consent may be given in 867 
two stages (if approved by the IRB), with one consent signature obtained prior to 868 
screening procedures specific to the SCORE Study that are needed to assess 869 
eligibility.  The second stage will be obtained prior to r andomization and will be for 870 
participation in the SCORE Study.  Thus, a single consent form will have two 871 
signature/date lines for the patient: one for the patient to consent to the screening 872 
procedures and one for the patient to consent for the randomized trial.  Patients will 873 
be encouraged to discuss the SCORE Study with family members and their personal 874 
physician(s) before deciding on study participation.  Two identical consent forms are 875 
signed.  One original consent form is to be kept in the participant’s study file and a 876 
copy of an original is placed in the participant’s clinical chart.  The other original 877 
signed consent is for the participant to take home.  The informed consent describes 878 
the study, randomization procedure, intravitreal steroid treatment and participant 879 
responsibilities.  Randomization will occur following confirmation of the patient’s 880 
eligibility for the study and decision to enter the study. 881 
 882 
4.5.2 Screening Evaluation 883 
a. An interview is conducted, including demographic information, medic al 884 
history including ocular history and current medications.  This history is 885 
taken in order to ascertain whether there is any medical, ocular, or 886 
medication condition that may indicate ineligibility.  Participants who are 887 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 33 taking aspirin or warfarin are eligible for the study .  However, 888 
participants may be requested to refrain from taking warfarin a few days 889 
prior to the randomization visit and/or any retreatment visits if they are 890 
assigned to receive corticosteroid treatment; this decision is at the 891 
discretion of the investigator and the patient’s primary care physician.   892 
b. Visual acuity and manifest refraction (done within 8 days prior to 893 
randomization) .  Visual acuity testing and manifest refraction are done 894 
using electronic ETDRS (E -ETDRS) visual acuity testing at 3 meters 895 
using the Electronic Visual Acuity Tester by a SCORE certified 896 
technician.  This testing procedure has been validated against 4 meter 897 
standard ETDRS chart testing.    Given the critical importance of visual 898 
acuity in this study, the best- corrected E -ETDRS visual acuity must be 899 
obtained in this very careful and standardized manner.  Additionally, a 900 
“masked” visual acuity examiner with no knowledge of treatment 901 
assignments will perform visual acuity testing  at the 4 -month, 12-month, 902 
24-month and 36-month visits.  This “masked” examiner will be an 903 
individual not involved with the study except for the purpose of performing 904 
visual acuity testing.  For example, this individual may be a clinic 905 
technician or a study coordinator for another clinical trial, but may not be 906 
the study coordinator for this trial.  907 
c. IOP (done within 21 days prior to randomization) .  The IOP of both eyes 908 
will be measured prior to randomization.  IOP will be measured using a 909 
sterile Goldmann applanation tonometer (see MOPP for procedure 910 
details).  911 
d. Ophthalmic examination including dilated ophthalmoscopy (done within 912 
21 days prior to randomization) .  The participant's ocular status is 913 
evaluated by a study participating ophthalmologist for conditions that may 914 
make the participan t ineligible as well as information necessary to 915 
complete the study forms.  Lens assessment for cataract at the slit lamp 916 
will be performed with grading according to a modified Age- Related Eye 917 
Disease Study (AREDS) grading system.  918 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 34 e. Fundus photographs, fluor escein angiography and optical coherence 919 
tomography (done within 21 days prior to randomization) .  Good quality 920 
stereoscopic color fundus photographs (7 fields of the study eye and 3 921 
fields of the fellow eye) and a fluorescein angiogram as well as two optical 922 
coherence tomography measurements per eye are required for all 923 
participants.  The mean of the 2 OCT measurements will be used to assess 924 
eligibility. These procedures are described in: University of Wisconsin- 925 
Madison Fundus Photograph Reading Center Fluorescein Angiography 926 
and Optical Coherence Tomography protocols. 927 
f. Blood pressure measurement (done within 21 days prior to 928 
randomization) . 929 
g. For women of childbearing potential: Urine pregnancy test (done within 21 930 
days prior to randomization) . 931 
 932 
4.5.3 Randomization 933 
A secure Internet -based eligibility, enrollment and randomization system is integrated 934 
into the SCORE Study.  One eye of each participant will be randomly assigned to 935 
either treatment with intravitreal triamcinolone acetonide in one of two doses (4 mg 936 
or 1 mg) vs. observation (CRVO) or intravitreal triamcinolone acetonide in one of 937 
two doses (4 mg or 1 mg) vs. observation/grid laser photocoagulation (BRVO).  938 
Treatment assignments, generated by the SCORE Data Coordinating Center, will be 939 
stratified ac cording to the following disease groups:  CRVO, BRVO without dense 940 
macular hemorrhage, and BRVO with dense macular hemorrhage; and baseline visual 941 
acuity according to the following categories: good visual acuity (59-73 letters: 20/40 942 
to 20/63), moderate vi sual acuity (49 -58 letters: 20/80 to 20/100), and poor visual 943 
acuity (19 -48 letters: 20/125-20/400).  In participants with both eyes eligible and 944 
when both eyes have the same disease (CRVO or BRVO), the eye to be randomized 945 
into the SCORE Study will be at the discretion of the physician and patient.  Only one 946 
eye per participant may be randomized into the SCORE study.  In participants with 947 
both eyes eligible, but where the disease is different (i.e. CRVO in one eye and 948 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 35 BRVO in the other eye) the eye to be r andomized into the SCORE Study will also be 949 
at the discretion of the physician and patient. 950 
 951 
4.6  Standard Care Groups  952 
For study eyes with CRVO, standard care consists of observation of the macular edema.  953 
For study eyes of BRVO participants with a dense macul ar hemorrhage, standard care is 954 
observation followed by grid laser photocoagulation if and when clearing of the 955 
hemorrhage permits grid laser photocoagulation.  For study eyes of BRVO participants 956 
without a dense macular hemorrhage at enrollment, standard care consists of immediate 957 
grid laser photocoagulation.  The determination of a dense hemorrhage in the center of the 958 
macula (and thus the timing of the grid laser photocoagulation) is left to the discretion of 959 
the investigator.  For all three groups, neovascular complications will be treated as 960 
necessary.  961 
 962 
The timing of, and criteria for, retreatment with laser photocoagulation are detailed in 963 
Section 4.8.3. 964 
 965 
4.6.1 Photocoagulation Procedures 966 
Participants with BRVO assigned to standard care who are eligible for laser (i.e., no 967 
dense macular hemorrhage) will have laser photocoagulation performed to treat both 968 
focal leaks, if any, and areas of diffuse retinal thickening.  The investigator has the 969 
flexibility to determine the total number of burns required for treatment.  However, 970 
the total number of burns delivered will depend on the number of focal leaks present, 971 
if any, and the area of diffuse retinal thickening present.  If the eye is not eligible for 972 
laser photocoagulation at the randomization visit because of t he presence of dense 973 
macular hemorrhage, the participant will be re- evaluated at 4 -month intervals.  If the 974 
macular hemorrhage clears, laser photocoagulation will be performed at that time.  975 
The following guidelines should be followed: 976 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 36 Grid Laser Photocoagu lation Procedure 977 
 
Size  
50-100 um  
 
Exposure   
0.05-0.1 seconds  
 
Intensity   
Mild  
 
Number   
Cover areas of diffuse retinal thickening and treat focal leaks if 
any are present  
 
Placement   
1-2 burn width apart (500 -3000um from center of fovea)  
 
Wavelength   
Green to yellow  
 978 
 979 
4.7   Intravitreal Steroid Groups  980 
Study eyes of CRVO and BRVO participants randomized to intravitreal steroid injection(s) 981 
will be given triamcinolone acetonide, in a masked fashion, in one of two doses (1 mg or 4 982 
mg), depending on the trea tment assignment.  983 
 984 
The timing of, and criteria for, retreatment with intravitreal triamcinolone injections are 985 
detailed in section 4.8.3. 986 
 987 
4.7.1 Intravitreal Injection of Triamcinolone Acetonide 988 
The study drug formulation (triamcinolone acetonide) used in the SCORE Study has 989 
been developed by Allergan, Inc. (Irvine, CA).  The physical, chemical and 990 
pharmaceutical properties of the study drug and formulation are detailed in the 991 
Clinical Investigator’s Brochure.  Topical antibiotic drops will be administered in the  992 
study eye prior to injection (on the day of injection) and for three days post injection.  993 
Prior to injection, a standard prep will include povidone iodine and a sterile lid 994 
speculum. The same technique is followed for both the initial treatment and for 995 
retreatment.  The full injection procedure is described in the SCORE Study MOPP. 996 
 997 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 37 4.8  Participant Visit Schedule, Retreatment, Alternate Treatment and Other 998 
Treatments  999 
Note: The SCORE Study protocol under protocol versions 6.0 and earlier specified 3 1000 
year foll ow-up on all study participants.  Under Protocol version 7.0 and higher 1001 
(February 10, 2008), the last day of enrollment is February 29, 2008 and the last day 1002 
of participant follow-up is February 28, 2009 to allow all participants at least one 1003 
year of follo w-up for primary efficacy assessment.  Testing procedures at a study 1004 
participant’s final study visit, which will take place at one of the following visits: M12, 1005 
M16, M20, M24, M28, M32, or M36, will be performed as described in Section 4.8.2.  1006 
Patients who are injected in February 2009 will still need to come in for their Day 4 1007 
and Month 1 safety visits, even though these safety visits may be late, i.e. they may 1008 
occur after February 28, 2009.  (Late safety visits are required to safeguard patient 1009 
safety, but, to ensure comparability between groups, late safety visits will not be part 1010 
of the trial safety analysis).  All study participants active under Protocol Version 7.0 1011 
who will not reach their Month 36 visit by February 28, 2009 will be asked to sign an 1012 
addendum to the informed consent form. 1013 
4.8.1 Visit Schedule  1014 
Appendix 1 shows the follow-up visit schedule for all participants through month 36. 1015 
Participants in each of the 3 treatment groups will have follow-up visits every 4 1016 
months.  The visit windows are ± 2 weeks during the first 12 months and ± 8 weeks 1017 
after 12 months. 1018 
• The visits at 4 months (± 2 weeks), 12 months (± 2 weeks), 24 months (± 1019 
8 weeks),  and 36 months (± 8 weeks) are designated for outcome 1020 
assessment visits.  At these visits, certain additional tes ting is performed 1021 
that is not performed at other visits.  1022 
• For the visits at 8, 16, 20, 28, and 32-months, the end of the visit window 1023 
may be extended if necessary so that the visit occurs no sooner than 3.5 1024 
months since the last treatment.  1025 
Additional visits  may occur as required for usual care of the study participant 1026 
• In the intravitreal triamcinolone groups, post- injection safety visits will be 1027 
performed at 4 days and 4 weeks after each intravitreal injection.  1028 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 38 • Assessment of ocular symptoms or ocular problems other than for macular 1029 
edema or the follow-up of adverse events may require additional visits.  1030 
These visits are to be scheduled promptly at the investigator’s discretion. 1031 
 1032 
4.8.2 Testing Procedures to be Performed at Follow -up Visits (see Appendix 1)  1033 
The following procedures will be performed at each 4 -month follow-up visit on both 1034 
eyes unless otherwise specified.  1035 
1. E-ETDRS visual acuity.  Protocol refraction will be performed at the 4, 1036 
12, 24 and 36 month visits.  At other visits, the need for a refraction is 1037 
determined by the investigator based on usual care considerations.  A 1038 
refraction should be performed when there is a change in visual acuity of 1039 
15 or more letters (better or worse) from the visual acuity score at the time 1040 
of the last refraction.  1041 
2. IOP me asurement using the Goldmann tonometer. 1042 
3. Ophthalmic examination, including a dilated fundus examination and a 1043 
slit-lamp examination.  1044 
4. Fundus photography. Three field fundus photography will be performed on 1045 
the study eye at all visits except at 12, 24, and 36 months, at which time 1046 
seven field fundus photography will be performed. Three field fundus 1047 
photography will be performed on the non-study eye at 12, 24, and 36 1048 
months. 1049 
5. Optical coherence tomography.  To be performed on both eyes at 4, 12, 24, 1050 
and 36 months and on the study eye only at other visits. 1051 
6. Lens assessment, using modified AREDS standard lens photographs, for 1052 
cataract will be performed at 4, 12, 24, and 36 months. 1053 
7. Fluorescein angiography will be performed at 4, 12, and 24 months.  The 1054 
fluorescein angiography protocol directs image capture from both eyes, 1055 
with emphasis on the study eye. 1056 
8. Blood pressure measurements will be performed at 12, 24, and 36 months. 1057 
 1058 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 39 Visual acuity, IOP, and an ophthalmic examination will be performed at the 4- 1059 
day (+/ -3 days) and 4- week (+/ -7 days) post- injection safety visits.  At 1060 
unscheduled visits, the procedures performed will be determined by the 1061 
investigator.  1062 
4.8.3 Retreatment Assessment  1063 
At each 4 -month visit during follow-up, the investigator will assess whethe r persistent 1064 
or recurrent macular edema is present that warrants retreatment with the 1065 
randomization assigned treatment.  1066 
 1067 
Only those eyes assigned to intravitreal triamcinolone and those eyes eligible for laser 1068 
photocoagulation (i.e. eyes with BRVO and without a dense macular hemorrhage) are 1069 
eligible for retreatment.  1070 
 1071 
Retreatment, when indicated, will be performed within 4 weeks after the follow-up 1072 
visit.  Retreatment should not be performed sooner than 3.5 months from the time of 1073 
the last treatment.  1074 
 1075 
If ret reatment is deferred because the patient has responded well to prior treatment, 1076 
then the patient can either be scheduled to be seen in 4 months or can be seen sooner 1077 
at investigator’s discretion.  1078 
 1079 
4.8.3.1 Retreatment Criteria  1080 
In general, the patient will be retreated with the randomization -assigned 1081 
treatment unless there are specific reasons not to retreat, in which case the 1082 
investigator may decide to postpone treatment, although postponing treatment 1083 
is not required.  The reasons for not retreating include: 1084 
 1085 
1. Treatment has been successful and may not need to be repeated if one of 1086 
the following is present:  1087 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 40 a. The investigator considers the center of the macula nearly flat. ( Note: 1088 
for the purposes of this study, as a guideline, the center of the macula 1089 
should not be considered flat if the OCT central subfield is greater 1090 
than 225 microns). 1091 
b. ETDRS visual acuity score of 79 or more letters (approximately 20/25 1092 
or better).  1093 
c. In the opinion of the investigator, there has been substantial 1094 
improvement in macular edema from the last treatment session (e.g., > 1095 
50% decrease in retinal thickening [thickening is not retinal thickness; 1096 
it is the difference between normal retinal thickness and observed 1097 
retinal thickness] in the central subfield) AND further spontaneous 1098 
improvement (without additional treatment) in macular edema might 1099 
be expected.  1100 
 1101 
2. Additional treatment is contraindicated because either the patient had a 1102 
significant adverse effect from prior treatment or maximum treatment has 1103 
already been received.  Examples include the following :   1104 
• The participant had an IOP elevation after a previous steroid 1105 
injection that required treatment to lower the IOP.  ( Note: an 1106 
investigator may choose to retreat a participant who developed 1107 
IOP elevation that has been controlled or is currently controlled 1108 
with treatment as long as IOP currently is 35 mm Hg or less.  If 1109 
the IOP is greater than 35 mm Hg, then the IOP must be lowered 1110 
before retreatment is given ).  1111 
• In the investigator’s judgment, maximum safe laser 1112 
photocoagulation has been performed and therefore additional 1113 
laser photocoagulation is contraindicated 1114 
 1115 
3. Additional treatment seems "apparently futile": 1116 
Additional treatment will be defined as "apparently futile" if 8 or more 1117 
months transpire, during which there have been 2 proce dures (either laser 1118 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 41 photocoagulation or intravitreal triamcinolone injection, according to the 1119 
randomization assigned treatment), and during which there is no evidence 1120 
of at least “borderline improvement.”   1121 
An eye is considered to have at least "borderlin e improvement" if it meets 1122 
either of the following criteria compared with the findings at the beginning 1123 
of the 8 or more months period: 1124 
a. An increase in visual acuity score of 5 or more letters.  1125 
or 1126 
b. A decrease in calculated retinal thickening (measured  thickness minus 1127 
175 microns in the OCT central subfield of the six- radial scan map) 1128 
that is at least 50 microns and represents at least a 20% reduction in 1129 
calculated retinal thickening (measured thickness minus 175 microns) 1130 
compared with the findings at the beginning of the 8 or more months 1131 
period. 1132 
If the eye meets the criteria for additional treatment being “apparently futile”, the 1133 
treating ophthalmologist may elect to discontinue further treatment at this visit.  1134 
However, the treating ophthalmologist is not obligated to discontinue treatment at 1135 
this visit and may perform an additional treatment (either laser photocoagulation 1136 
or intravitreal triamcinolone injection, according to the randomization assigned 1137 
treatment) if desired.  1138 
 1139 
Example of “Apparently Futile” at 20 Months After Study Enrollment 1140 
An eye improved in visual acuity from 55 letters (approximately 20/80) to 70 1141 
letters (approximately 20/40) and in OCT from 400 to 300 microns during the 1142 
first year of follow -up (i.e., at the 12-month follow-up the visual acuity was 70 1143 
letters (approximately 20/40) and the OCT measured 300 microns) and had 1144 
intravitreal injections at baseline, 6, 12, and 16 months.  Between 12 and 20 1145 
months the eye never had a visual acuity measured at better than 70 letters 1146 
(approximately 20/40) and the smallest OCT thickness measured was 290 (less 1147 
than 50 microns reduction from 300 microns measured at 12 months).  Because 1148 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 42 there is no evidence of at least “borderline improvement” during these last 8 1149 
months, the treating ophthalmologist may wish to discontinue treatment at this 1150 
visit.  However, continued treatment is not forbidden.  If treatment is 1151 
discontinued, the investigator may choose to reinstate treatment at a subsequent 1152 
visit (such as, if the investigator believes that vision and/or retinal thickening has 1153 
worsened).  1154 
 1155 
If the OCT thickness at the beginning of the 8 or more months period had been 1156 
500µm, a reduction of at least 65µm would have been required to meet the at 1157 
least borderline improvement definition (beginning calculated retinal thickening 1158 
500-175 = 325; 20% reduction = 65µm). 1159 
 1160 
Note:  This example is for a patient assigned to receive intravitreal triamcinolone 1161 
injection.  However, this example is also applicable for patients with BRVO and 1162 
without a dense macular hemorrhage who have received laser photocoagulation. 1163 
 1164 
4.8.4 Alternate Treatment for the Study Eye  1165 
Although it is preferable that study eyes assigned to standard care (i.e., laser 1166 
photocoagulation for BRVO eyes without a dense macular hemorrhage or 1167 
observation for CRVO eyes or observation for BRVO eyes with a dense macular 1168 
hemorrhage) not be treated with intravitreal triamcinolone acetonide and for study 1169 
eyes assigned to intravitreal triamcinolone acetonide not be treated with laser 1170 
photocoagulation, it is recognized that t here may be situations where the 1171 
investigator strongly believes that the alternate treatment should be provided. 1172 
 1173 
An eye may be treated with the alternate treatment when it has experienced:  1174 
1. A 15 -letter decrease from baseline in best -corrected visual acu ity that is 1175 
present at two consecutive 4 -month interval visits.   1176 
AND 1177 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 43 2. The decrease in visual acuity is due to persistent or recurrent macular edema 1178 
(i.e. not due to cataract or other abnormality) that is documented on OCT. 1179 
(Note: for the purposes of this study, as a guideline, the center of the macula 1180 
should not be considered flat if the OCT central subfield is >225 microns) . 1181 
 1182 
When the above criteria are met, an eye assigned to a standard care group may 1183 
receive (but is not required to receive) intravitreal triamcinolone (4 mg dose, study 1184 
formulation) and BRVO eyes without a dense macular hemorrhage assigned to 1185 
intravitreal triamcinolone injection may receive (but are not required to receive) 1186 
laser photocoagulation. When the above criteria are met, the investigator should 1187 
only provide the alternate treatment if the investigator strongly believes that the 1188 
alternate treatment is in the patient’s best interest.  1189 
 1190 
4.8.5 Other Treatments  1191 
If, in  the investigator’s judgment, the study eye requires additional treatment o ther 1192 
than laser photocoagulation or intravitreal triamcinolone injection, then the Study 1193 
Chair or Co -Chair should be contacted to discuss possible treatments.  However, 1194 
anti-inflammatory topical medication may be prescribed for treatment of the study 1195 
eye w ithout Study Chair or Co-Chair consultation. 1196 
 1197 
4.9  Diagnosis and Treatment of Adverse Events 1198 
4.9.1 Endophthalmitis Treatment  1199 
The decision to treat a patient for an endophthalmitis or a suspected endophthalmitis 1200 
will be guided by the clinical judgment of the investig ator.  The treatment method 1201 
(pars plana vitrectomy vs. vitreous tap) and choice of antimicrobial agents is also at 1202 
the discretion of the investigator and should follow current standard practice patterns. 1203 
 The decision to use intravitreal steroids (e.g. dex amethasone) for the treatment of 1204 
endophthalmitis is also at the discretion of the investigator.  1205 
 1206 
4.9.2 Treatment of Elevated Intraocular Pressure (IOP)  1207 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 44 It is expected that some patients will have an IOP rise that may require treatment to 1208 
lower the IOP.  1209 
 1210 
Treatment of elevated IOP will be instituted whenever the IOP is greater than or equal 1211 
to 30 mm Hg.   The treatment to prescribe will be at investigator discretion and may 1212 
include referral to another ophthalmologist.  If the IOP is between 22 and 30 mm Hg, 1213 
then the IOP should be measured again within one month and treated if greater than or 1214 
equal to 30 mm Hg.  IOP greater than 25 mm Hg at consecutive 4-month visits should 1215 
be treated.  If IOP is greater than 25 mm Hg for 4 months, then a visual field should 1216 
be performed to evaluate for glaucomatous damage.  1217 
 1218 
The treatment to prescribe is at the discretion of the investigator and may include 1219 
referral to another ophthalmologist.  One treatment regimen that can be followed was 1220 
used in the Collaborative Initial Glaucoma Treatment Study53 and is listed below:  1221 
 1222 
Participants may receive a sequence of medications, which may begin with a topical 1223 
beta-blocker, followed by an alternate single topical therapeutic agent, dual topical 1224 
therapy, triple topical therapy, an alternate combination of triple topical therapy, and 1225 
an optional additional topical and/or oral medication or medications.  If further 1226 
treatment is required, the next treatment step may be argon laser trabeculoplasty, 1227 
followed by trabeculectomy, medication, trabeculectomy with an antifibrotic agent, 1228 
and medication. 1229 
 1230 
4.9.3 Cataract Surgery  1231 
It is expected that some study participants in both the intravitreal steroid arms and the 1232 
standard care arms will develop cataract within the study period.  The decision to 1233 
perform cataract surgery is at the discretion of the investigator and the patient.  1234 
Indications for cataract surgery should follow guidelines developed by the American 1235 
Academy of Ophthalmology, Preferred Practice Pattern (Cataract in the Adult Eye, 1236 
Anterior Segment Panel , 2001, page 15).  Similar guidelines have been adopted by the 1237 
Department of Health and Human Services (Medicare Program; Limitations on 1238 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 45 Medicare Coverage of Cataract Surgery, October 6, 1995):  1239 
Indications for Cataract Surgery:  1240 
1. Visual function that no long er meets the participant’s needs and for which 1241 
cataract surgery provides a reasonable likelihood of improvement. 1242 
2. Lens opacity that inhibits optimal management of posterior segment disease.  1243 
3. The lens causes inflammation (phakolysis, phakoanaphylaxis), angle 1244 
closure, or medically unmanageable open -angle glaucoma.  1245 
 1246 
Participants in both  the intravitreal steroid groups and the standard care groups 1247 
should be assessed for the development of cataract in a similar fashion. Cataract 1248 
surgery may be performed at any tim e that this is indicated clinically.  1249 
 1250 
4.9.4 Surgery for Proliferative Retinopathy and Other Complications Due to 1251 
Retinal Vein Occlusion  1252 
It is expected that some study participants will develop vitreous hemorrhage and/or 1253 
other complications of retinal vein occlus ion that may cause visual impairment.  1254 
Vitrectomy for the complications of proliferative retinopathy such as vitreous 1255 
hemorrhage should be delayed, if clinically feasible, because vitreous hemorrhage 1256 
may resolve, obviating the need for vitrectomy.  Furthermore, vitrectomy is thought to 1257 
reduce the half -life of intravitreal steroids such that participants assigned to the 1258 
steroid treatment arms may experience reduced benefit from intravitreal steroid 1259 
injections following vitrectomy.  1260 
 1261 
A suggested treatment plan  that may be followed for eyes with vitreous hemorrhage 1262 
and/or other complications of retinal vein occlusion is as follows: 1263 
1. Eyes with visually significant, non -clearing vitreous hemorrhage should 1264 
have vitrectomy performed if there is no significant clearin g in 3 months. 1265 
2. Eyes with traction retinal detachment involving or threatening the fovea 1266 
should have vitrectomy performed as soon as clinically indicated. 1267 
3. Eyes with a combined traction -rhegmatogenous retinal detachment should 1268 
have vitrectomy performed as so on as clinically indicated.  1269 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 46 4. Eyes with extensive and progressive fibrovascular proliferation should have 1270 
vitrectomy performed as soon as clinically indicated.  1271 
5. Eyes with vitreoretinal interface disease such as from vitreomacular traction 1272 
or an epiretinal mem brane can, at the discretion of the investigator, have 1273 
vitrectomy performed if the investigator believes that the primary cause of 1274 
macular edema and reduced visual acuity is due to the vitreoretinal interface 1275 
disease.   1276 
 1277 
4.10 Miscellaneous Treatments During Fol low-up 1278 
4.10.1 Treatment of Macular Edema in Non -study Eye 1279 
If a non- study eye that was not eligible for enrollment develops macular edema 1280 
associated with retinal vein occlusion requiring treatment, the treatment will depend 1281 
on the randomization group of the study eye.  The following also applies to the non- 1282 
study eye of a patient who presents with both eyes eligible for the SCORE study at 1283 
screening and when both eyes have the same disease (CRVO or BRVO) or if each eye 1284 
has a different disease (i.e. one eye has a CRVO  and the other eye has a BRVO).  1285 
• If the study eye was assigned to an intravitreal corticosteroid group, then 1286 
the non- study eye will receive standard care to avoid treating both eyes 1287 
with intravitreal corticosteroids.   1288 
• If the study eye was assigned to stand ard care, then the non- study eye may 1289 
be treated with either intravitreal corticosteroids (study preparation, 4 mg 1290 
dose only) or standard care at investigator/patient discretion.  A non-study 1291 
eye treated with the study steroid preparation will undergo the s ame follow - 1292 
up schedule, retreatment regimen and adverse event monitoring as study 1293 
eyes in the SCORE Study. 1294 
 1295 
4.10.2 Panretinal Photocoagulation (PRP) Treatment: 1296 
PRP or sector PRP can be given if it is indicated in the judgment of the investigator 1297 
and following gui delines established by the CVOS and BVOS.  Recall that 1298 
participants are not eligible for the SCORE Study if, at the time of randomization, it 1299 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 47 is expected that they will need PRP within 4 months.  The following guidelines 1300 
should be followed: 1301 
Burn Characteristics  1302 
 1303 
Size (on retina)  500 microns  
Exposure  0.1 seconds recommended, 0.05 to 0.2 allowed 
Intensity mild white  
Distribution  edges 1 burn width apart  
No. of Sessions/Sittings  unrestricted (each session generally should be completed in <6 sittings)  
Nasa l proximity to disk  No closer than 500 microns  
Temp. proximity to center No closer than 3000 microns  
Superior/inferior limit  No further posterior than 1 burn within the temporal arcades  
Wavelength  Green to yellow (red can be used if vitreous hemorrhage is present 
precluding use of green or yellow)  
 1304 
5. Data Monitoring and Adverse Event Reporting 1305 
5.1 Data Safety Monitoring Committee 1306 
The SCORE Data and Safety Monitoring Committee (DSMC) is responsible for reviewing 1307 
the study design and, as appropriate, recommending design changes to the SCORE 1308 
Executive Committee and the NEI.  The DSMC also may recommend to the NEI to 1309 
suspend enrollment if adverse events predominate.  In addition, the DSMC assesses study 1310 
data, particularly for adverse and/or beneficial effects of treatment.  The DSMC is expected 1311 
to meet at least every six months and will review all accumulating study data including 1312 
adverse events.  The SCORE Data Coordinating Center (DCC) will report to the DSMC 1313 
expeditiously, on a case-by- case basis, specific adverse events described in the DSMC 1314 
Standard Operating Procedure document.  In addition, the DSMC will review early safety 1315 
data on patients from the SCORE Study and from the Diabetic Retinopathy Clinical 1316 
Research Network (DRCR.net) study on intravitreal tri amcinolone and diabetic macular 1317 
edema.  Both studies are served by the same DSMC and both studies will use the same drug 1318 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 48 formulation.  The SCORE Study will not proceed if there are any serious concerns 1319 
identified with the formulation or the injection procedure.  The monitoring plan that the 1320 
DSMC will follow is: 1321 
• An initial report will include the day 4 follow -up data from the first 5 patients 1322 
(combined in the DRCRnet and SCORE studies) who receive an intravitreal 1323 
triamcinolone injection.  No additional patients will receive an intravitreal 1324 
injection until these data have been obtained and it is clear that there are no 1325 
immediate safety concerns.  1326 
• A second report will be compiled after 5 patients have completed the 4-week post 1327 
injection exam.  It will include th e 4-day data on a second group of 5 patients. 1328 
Note: no more than 10 patients will receive intravitreal injections until the first 5 1329 
patients have completed at least 4 weeks of follow up.  Thereafter, assuming that 1330 
there have not been any unexpected consequences of the injections, enrollment 1331 
will be opened to all sites.  1332 
• A third report will be compiled after 10 patients who receive an intravitreal 1333 
triamcinolone injection have completed the 4- week post injection exam.  1334 
Thereafter, assuming that there have been no safety concerns, the data will be reviewed 1335 
on a monthly basis by the DSMC until the committee is comfortable with reviewing the 1336 
data on a less frequent schedule.  1337 
 1338 
5.2 Methods and Timing for Assessing, Recording and Analyzing Safety Parameters 1339 
Each clinical site is responsible for reporting all adverse events, including toxicities, that 1340 
occur to SCORE participants enrolled at their site, regardless of relatedness to study 1341 
therapy or procedure.  Reporting of all adverse event data is expected upon recognition. 1342 
 1343 
Serious adverse events (SAEs), as defined in Section 5.3.1.2 must be reported to the 1344 
SCORE DCC within 24 hours of recognition.  Study investigators must report serious 1345 
adverse events to their local ethics review committee (or IRB) promptly in accordance with 1346 
local regulations or policies in addition to the SCORE DCC.  The SCORE DCC may 1347 
request additional information regarding adverse events from investigators following their 1348 
initial review.  1349 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 49  1350 
5.3 Procedures for Reporting Adverse Events  1351 
Clinical sites are required to report all adverse events via the SCORE electronic data 1352 
capture system (AdvantageEDCSM).  Each site will receive training on reporting 1353 
requirements.  Electronic forms that are designed to collect adverse event data will be 1354 
available for input at an y time, including between scheduled visits. 1355 
 1356 
When a reported adverse event is determined to be serious, unexpected, and to have a 1357 
reasonable possibility to be related to the test product or procedure, or otherwise reportable 1358 
to regulatory agencies or drug manufacturers, the SCORE DCC will prepare an initial 1359 
report as described below.  Cumulative reports of other adverse events not considered 1360 
serious will also be prepared by the SCORE DCC and reviewed by the Medical Monitor on 1361 
at least a monthly basis, and by the DSMC on a routine basis at least semi -annually. 1362 
 1363 
5.3.1 Routine SCORE DCC Review  1364 
The SCORE DCC Medical Monitor will be provided relevant material in order to 1365 
assess whether there are safety concerns that may require expedited reporting to the 1366 
FDA, DSMC, loc al ethics committee (or IRB), study investigators, the pharmaceutical 1367 
manufacturer, or the study sponsor (National Eye Institute).  A report of new adverse 1368 
events will be reviewed each weekday by the SCORE DCC.  Other data are reviewed 1369 
weekly by the SCORE DCC.  1370 
 1371 
5.3.1.1 Definition of Adverse Event  1372 
An adverse event (AE) is defined as any untoward medical occurrence in a 1373 
patient or clinical investigation subject administered a pharmaceutical product 1374 
and that does not necessarily have a causal relationship with this tr eatment.  An 1375 
adverse event can therefore be any unfavorable and unintended sign (including 1376 
an abnormal laboratory finding), symptom, or disease temporally associated 1377 
with the use of a medicinal (investigational) product, whether or not related to 1378 
the medic inal (investigational) product. 1379 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 50 • Unexpected Adverse Drug Reaction – An adverse reaction, the nature or 1380 
severity of which is not consistent with the applicable product 1381 
information (e.g. Investigator’s Brochure for an unapproved 1382 
investigational product or package insert / summary of product 1383 
characteristics for an approved product.). 1384 
 1385 
Throughout the study, all adverse events must be recorded in the 1386 
AdvantageEDC, regardless of the severity or relationship to study medication or 1387 
procedure.  If an adverse event is caused by a combination of treatment and 1388 
disease, the adverse event should be graded as it is observed.  Early in the 1389 
development of a therapy, when little is known about the therapy’s safety 1390 
profile, it is especially important to maintain a high level of  suspicion and report 1391 
adverse events that may be treatment -related adverse events.  This reporting may 1392 
facilitate identification of idiosyncratic or low frequency treatment- related 1393 
adverse events.  1394 
 1395 
5.3.1.2 Serious Adverse Event (SAE)  1396 
A serious adverse event (SAE) is defined as any adverse event occurring at 1397 
any dose that results in any of the following outcomes: 1398 
a. Death;  1399 
b. Life-threatening adverse event*;  1400 
c. In-patient hospitalization or prolongation of existing hospitalization; 1401 
d. Persistent or significant disability / inca pacity;  1402 
e. Congenital anomaly / birth defect.  1403 
* Including any adverse drug experience that places the patient or subject, 1404 
in the view of the investigator, at immediate risk of death from the reaction 1405 
as it occurred (i.e., it does not include a reaction that, had it occurred in a 1406 
more severe form, might have caused death). 1407 
 1408 
Important medical events that may not result in death, be life -threatening, or 1409 
require hospitalization may be considered a serious adverse event when, 1410 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 51 based upon appropriate medical judgment , they may jeopardize the patient 1411 
or subject and may require medical or surgical intervention to prevent one of 1412 
the outcomes listed in this definition.  1413 
 1414 
5.3.1.3 Expected and Unexpected Adverse Event  1415 
All adverse events, be they routine or serious, will be classifie d as either 1416 
expected or unexpected.  Any adverse therapeutic experience that is associated 1417 
with the study therapy or procedure and is listed as such in an investigational 1418 
plan, investigational brochure, protocol or informed consent is an expected 1419 
event.  I n contrast, any adverse therapeutic experience, the specificity or severity 1420 
of which is not  consistent with the investigational plan, investigator brochure, 1421 
protocol, or informed consent for the therapy is an unexpected event. 1422 
 1423 
5.3.2   Adverse Event Severity Gra ding  1424 
Severity grades are assigned by the study site to indicate the severity of all adverse 1425 
experiences.  The SCORE Study has adapted usage of The National Cancer Institute's 1426 
Common Terminology Criteria for Adverse Events (CTCAE) for application in adverse 1427 
event reporting.  A copy of the CTCAE system can be found on the SCORE website: 1428 
(http://www.emmes.com/ ). 1429 
 1430 
The CTCAE provides a term and a grade that closely describes the adverse event.  1431 
The CTCAE grade for each adverse event should be associated with a severity 1432 
category:  Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life- 1433 
threatening) and Grade 5 (Death).  If the adverse event is not included in the CTCAE, 1434 
the following general definitions should be us ed in determining severity: 1435 
 1436 
Grade 1   Mild   Transient or mild discomforts (<48 hours), no or minimal 1437 
medical intervention/therapy required, hospitalization not 1438 
necessary (nonprescription or single-use prescription 1439 
therapy may be employed to relieve sympto ms, e.g., 1440 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 52 aspirin for simple headache, acetaminophen for post- 1441 
surgical pain).  Mild adverse effects are an expected 1442 
consequence of the SCORE protocol used here, and 1443 
standard supportive therapies (per institutional guidelines) 1444 
are permitted.  1445 
Grade 2   Moderate  Mild to moderate limitation in activity, some assistance 1446 
may be needed; no or minimal intervention/therapy 1447 
required, hospitalization possible. 1448 
Grade 3   Severe  Marked limitation in activity, some assistance usually 1449 
required; medical intervention/thera py required, 1450 
hospitalization possible. 1451 
Grade 4  Life- threatening  Extreme limitation in activity, significant assistance 1452 
required; significant medical/therapy intervention 1453 
required, hospitalization or hospice care probable. 1454 
Grade 5   Death   Death.  1455 
 1456 
5.3.3 Relation to Therapy  1457 
The physician acting as the Principal Investigator at each study site or his/her 1458 
physician designee  should make the determination of therapy- relatedness of an 1459 
adverse experience.  A therapy -related determination must be made for every adverse 1460 
event, regardless of severity or event type (routine AE or SAE).  A causal relationship 1461 
is present if a determination is made that there is a reasonable possibility that the 1462 
adverse event may have been caused by the study drug. 1463 
 1464 
5.3.4 Adverse Event Reporting Requirements and Procedures for Clinical Sites 1465 
to the SCORE Coordinating Center  1466 
All adverse events, deaths, infections, and hospitalizations, regardless of severity, 1467 
expectedness, or potential association with the investigational drug, will be entered on 1468 
the appropriate form in the AdvantageEDC. 1469 
 1470 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 53 5.3.4.1 Requirements  1471 
Clinical sites are required to enter all known adverse event data from all 1472 
events into the electronic adverse event form in the AdvantageEDC. 1473 
 1474 
Serious adverse events are required to be entered into the AdvantageEDC 1475 
within 24 hours of recognition.  If all information required on the event form 1476 
has not been obtained, the site should submit what is available.  Additional 1477 
information, as it becomes available, can be submitted at a later date.  1478 
 1479 
5.3.5 Reporting Procedures  1480 
For reporting of AEs and SAEs, t he Site Coordinator will: 1481 
1. Complete an Adverse Event form (page 1) in the SCORE data entry 1482 
system.  1483 
2. If the site determines that the event is serious , the site will complete, in 1484 
detail, the Adverse Event Summary (page 2 of the Adverse Event Form). 1485 
3. The SCORE Medical Monitor will review the Adverse Event Summary 1486 
and complete an Adverse Event Review form (page 3 of the Adverse 1487 
Event form).  1488 
4. If follow -up information is required, the SCORE DCC will contact the 1489 
site. 1490 
5. If rapid repor ting is required, the SCORE DCC will prepare a MedWatch 1491 
and forward copies of the completed MedWatch to the SCORE Study 1492 
Chair and Co-Chair, DSMC Chair, and IND sponsor who will send the 1493 
MedWatch to the FDA.  1494 
 1495 
5.3.6 SCORE Adverse Event Reporting Contact  1496 
The SCORE Project Director (listed in the Data Management Handbook as well as 1497 
the current MOPP) may be contacted at the SCORE DCC, The EMMES Corporation, 1498 
located in Rockville, Maryland.  Be sure to clearly indicate the protocol number and 1499 
the location of your site w hen contacting the SCORE DCC.  Back -up personnel and 1500 
procedures are in place to assure that if the Project Director is not available, other 1501 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 54 personnel at the SCORE DCC can adequately handle requests or adverse event 1502 
reporting requirements.  For urgent AE requests that occur after business hours (8:30 1503 
– 5:00 Eastern Time), contact: 1504 
Maria Figueroa, MBA, CCRP  1505 
SCORE Project Director  1506 
The EMMES Corporation 1507 
Tel. ( 240) 344-1935 1508 
 1509 
5.4 Procedure for Reporting of Pregnancy  1510 
At the time a site Principal Investigator or Study Coordinator becomes aware that a study 1511 
participant has become pregnant during the study, the Principal Investigator or Study 1512 
Coordinator will prepare a report on the pregnancy to be sent to the SCORE DCC that 1513 
includes the following elements: 1514 
• Participant (mother’s) coded study identifier(s); 1515 
• Date of last menstrual period; 1516 
• Date of enrollment; 1517 
• Date(s) of fluorescein  angiogram(s); and  1518 
• Date of last intravitreal injection or laser treatment, if any.  1519 
 1520 
Any pregnancy that occurs during the study should be followed until the time of delivery, 1521 
miscarriage or abortion.  A report with any relevant information on the condition of the 1522 
fetus or infant at birth should be forwarded to the SCORE DCC, including: 1523 
• Mother’s coded study identifier(s); 1524 
• Gestational age at delivery, m iscarriage, or abortion; 1525 
• Birth weight, gender, length, and head circumference, if available; 1526 
• Apgar scores recorded after birth, if available;  1527 
• Any abnormalities.  Report all abnormalities as a serious adverse event.  1528 
 1529 
6. Statistical Considerations 1530 
6.1 Scientific and Regulatory Objectives  1531 
The SCORE Study’s scientific and regulatory objectives are to compare the efficacy and 1532 
safety of standard care with intravitreal injection(s) of triamcinolone acetonide (4 mg or 1 1533 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 55 mg) to treat macular edema associated with CRVO and BRVO.  Although scientific goals 1534 
parallel regulatory goals, regulatory requirements demand some divergence of scientific 1535 
statistical methods from regulatory statistical methods for testing the null hypothesis of no 1536 
treatment effect of triamcinolone acetonide.  Section 6.2 describes the formal test to be 1537 
performed for drug registration, while the remaining sections describe the scientific 1538 
statistical approach.  The DSMC will be responsible for monitoring the SCORE Study 1539 
following the scientific plan only . 1540 
 1541 
6.2 Formal Regulatory Statistical Test of Efficacy 1542 
For regulatory purposes, the SCORE Study will be configured as two separate and 1543 
independent clinical trials “A” and “B”, each trial to serve as confirmatory of the other.  To 1544 
accomplish this, clinical sites will be allocated before recruitment commences to either trial 1545 
“A” or trial “B”, using a method that strives for comparable geographic patterns and 1546 
distributions of enrollees per center .  Within each trial, CRVO and BRVO disease areas 1547 
will be pooled f or analysis and three primary efficacy analyses performed after no more 1548 
than one year of follow-up.  A detailed description of the method of assigning sites to Trial 1549 
“A” and Trial “B” is provided in the SCORE Study Manual of Procedures and Policies 1550 
(MOPP).   The assignment of sites to Trial “A” and Trial “B” will be made prior to 1551 
recruitment of subjects.  One analysis will compare 1 mg steroid versus standard care, one 1552 
will compare 4 mg steroid versus standard care, and one will compare 1 mg versus 4 mg 1553 
steroid.  The comparison will be with respect to the primary outcome measure.  The 1554 
primary outcome measure indicates whether or not a study eye of a participant experiences 1555 
an improvement of 15 or more letters from baseline in best- corrected ETDRS visual acuit y 1556 
score.  The significance of the three comparisons will be obtained by Hochberg’s 1557 
sequentially rejective procedure, as described in detail in the MOPP, section 6.2.  The 1558 
overall alpha for the A trial will be no more than 0.05, and similarly for the independent B 1559 
trial (more specifically, the alpha for each of the “A” and “B” trials will be diminished from 1560 
0.05 by the amount of alpha previously spent on interim scientific efficacy assessments).  1561 
Within trial “A” and within trial “B”, an initial analysis of treatment effect will be carried 1562 
out by logistic regression to determine whether a statistical interaction exists between 1563 
disease group (BRVO and CRVO) and treatment group (standard care, 4 mg steroid, and 1 1564 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 56 mg steroid).  A finding of no interaction effect will provide justification for pooling the 1565 
CRVO and BRVO participants within trial “A” and trial “B” and the primary efficacy 1566 
analyses for regulatory purposes, as described above, will be carried out by means of 1567 
logistic regression adjusting for disease a rea, baseline visual acuity, and center.  A 1568 
statistically significant interaction effect will require separate primary efficacy analyses for 1569 
CRVO and for BRVO within trial “A” and with trial “B”.  1570 
 1571 
6.3 Scientific Statistical Approach  1572 
6.3.1 Two Independent C linical Trials  1573 
The SCORE Study consists of two separate independent clinical trials - one for 1574 
CRVO and one for BRVO.  Each of these clinical trials has its own overall Type I 1575 
error (alpha) = .05. 1576 
 1577 
6.3.2 Three Primary Questions in Each Clinical Trial  1578 
Each o f these clinical trials asks three questions.  One question is the comparison of 1579 
standard care to 4 mg intravitreal injection(s) of triamcinolone acetonide.  A second 1580 
question is the comparison of standard care to 1 mg intravitreal injection(s) of 1581 
triamcin olone acetonide.  The third question compares 1 mg to 4 mg intravitreal 1582 
injections.  Within each clinical trial, the significance of the comparisons will be 1583 
obtained by Hochberg’s sequentially rejective procedure using an alpha level of 0.05 1584 
(see the MOPP,  section 6.4).  1585 
6.3.3 Primary Efficacy Outcome Measure and Time Point  1586 
Improvement by 15 or more letters from the randomization visit visual acuity to the 1587 
12-month follow- up visual acuity is the primary efficacy outcome measure.  Visual 1588 
acuity is to be meas ured using E- ETDRS visual acuity testing.  1589 
 1590 
6.3.3.1 Primary Efficacy Analysis Method 1591 
The three treatment comparisons (1 mg versus standard care, 4 mg versus 1592 
standard care, and 1 mg versus 4 mg) will be made by means of logistic 1593 
regression adjusting for base line visual acuity, clinical site, and presence of 1594 
baseline macular hemorrhage in participants with BRVO.  The test statistic 1595 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 57 will be compared to the critical value of the efficacy monitoring guideline 1596 
(section 6.7.2).  Family- wise error will be controlled at no more than 0.05 by 1597 
Hochberg’s sequentially rejective method, modified for interim monitoring as 1598 
specified in the MOPP.  1599 
 1600 
The analysis will be on the basis of intent to treat (ITT), treating missing 1601 
observations as missing completely at random [i.e., missing data from study 1602 
participants will be dropped from the analysis and noncompliance (or 1603 
treatment crossover) ignored].   1604 
 1605 
6.3.3.2 Additional Analysis Methods for Consistency of Primary 1606 
Efficacy Result  1607 
We will investigate two other ITT variants: (1) last-observation- carried - 1608 
forward (LOCF) and (2) performing a sensitivity analysis in which outcomes 1609 
will be assigned to missing eyes so as to explore both the minimum and 1610 
maximum possible estimates of treatment effects.  A per -protocol analysis, 1611 
excluded from which will be those study participants who drop out, cross over 1612 
to another treatment group, or violate the protocol, also will be conducted 1613 
including only study eyes that have completed 12-month visual acuity data.  1614 
Logistic regression analysis will be per formed to adjust for any potential 1615 
imbalances in baseline characteristics observed between treatment groups, 1616 
with the odds ratio used as a measure of increased or decreased risk.  1617 
Important baseline differences, not necessarily based on tests of statistical 1618 
significance, will be investigated as to their ability to confound the association 1619 
between the treatment groups and the primary outcome.  Although the intent- 1620 
to-treat analysis described in section 6.3.3.1 is considered to be the definitive 1621 
analysis, thes e additional analyses (e.g. other ITT variants, per- protocol) will 1622 
be used to explore the consistency of the result and provide more information 1623 
as to the benefit or lack of benefit of the treatment.  1624 
 1625 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 58 6.4 Assumptions for and Result of Sample Size Estimatio n 1626 
6.4.1 Study Power  1627 
The study power is set for each trial at 80%.   1628 
 1629 
6.4.2 Estimate of CRVO Primary Efficacy Outcome in the Standard Care Group  1630 
The Central Vein Occlusion Study (CVOS) demonstrated that in participants with 1631 
macular edema for more than 3 months secondary to a CRVO, macular grid laser 1632 
photocoagulation, as compared to no treatment, did not improve visual acuity.4 There 1633 
were no significant differences between treated and untreated participants in either 1634 
level of visual acuity or change in visual acuity across all follow -up visits.  The data 1635 
from the CVOS demonstrate that at 2 years from baseline 18% of treated eyes (10 of 1636 
57 eyes) and 11% of untreated eyes (6 of 53 eyes) experienced a gain of three or more 1637 
lines of visual acuity.  At 1 year, approximately 6% in both the treated and untreated 1638 
eyes showed a gain of three or more lines of visual acuity.  From these data, it is 1639 
conservatively estimated that approximately 15% of untreated eyes with CRVO will 1640 
experience a gain of three or more lines of visual acuity at 1 year.  1641 
 1642 
6.4.3 Estimate of BRVO Primary Efficacy Outcome in the Standard Care Group  1643 
In the Branch Vein Occlusion Study (BVOS), macular grid laser photocoagulation 1644 
was demonstrated to be effective in improving visual acuity in some eyes wit h BRVO 1645 
complicated by macular edema.1 Treatment resulted in a two or more line 1646 
improvement in visual acuity for two or more consecutive visits in approximately 1647 
45% of eyes at the 2 -year follow -up.  At one year, approximately 20% of treated eyes 1648 
gained two or more lines of visual acuity at two or more consecutive visits.  Patients 1649 
in the BVOS all had absence of dense macular hemorrhage before enrollment.  In the 1650 
SCORE Study, we anticipate as many as 50% of participants may have a dense 1651 
macular hemorrhage at enrollment and therefore will have grid laser treatment 1652 
postponed until the hemorrhage clears to permit treatment.  It is uncertain how the 1653 
inclusion of these eyes will affect efficacy in the standard care arm of the SCORE 1654 
study.  From these data, it is conservatively estimated that approximately 35% of 1655 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 59 standard care eyes will experience a gain of three or more lines of visual acuity at 1 1656 
year.  1657 
 1658 
6.4.4 Background Information on Efficacy of I ntravitreal Injection(s) of 1659 
Triamcinolone Acetonide 1660 
In Table 4, we provide outcomes of treatment with intravitreal steroid injections 1661 
based on six published reports of case series.  Data concerning diabetic macular 1662 
edema (DME) are included because of the similarity (VEGF related vascular 1663 
permeability) between DME and macul ar edema due to retinal vein occlusion. 1664 
Table 4  1665 
  
# of 
eyes 
treated   
Disease   
Dose 
(mg)  
Anatomical 
improvement  
Mean baseline 
visual acuity   
Mean visual 
acuity at 
endpoint   
Follow -
up 
(mos)  
 
Martidis33  
16  
DME   
  4  
11/16 (69%)   
20/200   
20/80   
3 
 
Jonas41  
26  
DME   
25  
21/21 (FA)   
20/160   
20/100     
6.6 
 
Jonas37  
  2  
CRVO  
25  
2/2 (100%)   
20/160   
20/125   
3 
 
Greenberg35  
  2  
CRVO  
  4  
2/2 (100%)   
20/400   
20/160     
4.5 
 
Ip36  
  2  
CRVO   
  4  
1/2 (50%)   
20/200   
20/100   
6 
 
Park38  
10  
CRVO   
4  
10/10 (10 0%)  
20/80   
20/32   
4.8 
 1666 
Except for Park et al,38 the six case series above did not use standardized methods to 1667 
measure visual acuity.  However, all six studies indicate a high likelihood of 1668 
significant visual acuity improvement for treatment of macular edema with 1669 
intravitreal triamcinolone acetonide.  The report by Martidis33 showed 11 of 16 1670 
DME eyes (69%) having a 3- line improvement in visual acuity at the last follow -up 1671 
visit for each eye, which was either 3 or 6 months after the intravitreal injection.  1672 
Park et al38 showed that 7/10 (70%) had a 3 or more line improvement after a mean 1673 
of 4.8 months follow up.  Further, unpublished data (Martidis et al and Ip et al), 1674 
some of which were presented at the 2002 Retina Congress (San Francisco, CA), 1675 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 60 provide addi tional evidence of the efficacy of this treatment for macular edema 1676 
secondary to retinal vein occlusion and diabetic macular edema.  Martidis et al, at 1677 
the 2002 Retina Congress, reported additional information on efficacy for DME: 1678 
73/125 (58%) had a two or more Snellen line improvement at an average follow -up 1679 
of 6.7-months.  For BRVO with prior laser treatment, 6/13 (46%) had a three or 1680 
more Snellen line improvement at 6 months.  Ip et al, at the 2002 Retina Congress, 1681 
reported additional information on effi cacy for CRVO (three Snellen line 1682 
improvement): 3/8 (38%) had a three or more Snellen line improvement at 6 1683 
months.   1684 
 1685 
6.4.4.1 Estimate for CRVO Primary Efficacy Outcome in the 1686 
Intravitreal Injection(s) Groups  1687 
For CRVO eyes, our projected rate of improvement of 15 or more letters at 1688 
one year is 30% in the 1 mg and in the 4 mg injection group.   1689 
 1690 
6.4.4.2 Estimate for BRVO Primary Efficacy Outcome in the 1691 
Intravitreal Injection(s) Groups  1692 
For BRVO eyes in the SCORE Study, in which all eyes will not have had pri or 1693 
laser treatment, we expect efficacy for eyes receiving intravitreal injection(s) 1694 
of triamcinolone to be higher, and project 53% will have an improvement of 1695 
15 or more letters at 1 year in the 1 mg and in the 4 mg group. 1696 
6.4.5 Sample Size Estimate 1697 
The sample size estimate (number per group) was computed assuming the efficacy in 1698 
the two steroid doses are the same.  If the efficacy in the 4 mg group is higher than the 1699 
1 mg group, and given the other preceding assumptions, the study power will be 1700 
higher for the standard care versus 4 mg comparison.  This was considered important 1701 
because the 4 mg dose is the basis for all available information. 1702 
 1703 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 61     Sample Size Estimate 1704 
  Type I error (alpha) = .025, study power = 80% 1705 
     CRVO    BRVO  1706 
  Standard care  15%   35% 1707 
  1 mg or 4 mg  30%   53% 1708 
  N per group  147   147 1709 
The allocation ratio will be 1:1:1 for standard care: 1 mg: 4 mg.  The number per 1710 
group has been increased by 10% to allow for some missing data at 12 months 1711 
(number per group=162).  Thus, the total sample estimate for the CRVO trial is 486 1712 
(3 times 162) and for the BRVO trial the total sample estimate is 486 (3 times 162).   1713 
 1714 
6.5 Safety Outcomes  1715 
Safety outcomes that will be assessed include serious adverse events and specific ocular 1716 
events requested by the Data and Safety Monitoring Committee.  The SCORE Study DCC 1717 
and DSMC will continuously monitor the following safety indicator variables: 1718 
• Cataract  1719 
• IOP exceeding 35 while on maximal medical therapy  1720 
• Filtration surgery to lower IOP  1721 
• Non-infectious endophthalm itis 1722 
• Any of: infectious endophthalmitis, retinal detachment, vitreous hemorrhage, loss of 1723 
20 ETDRS letters at 4 days or 4 week post injection, a new -onset retinal arterial 1724 
occlusion, a transition from a branch to a central retinal vein occlusion, a new, 1725 
clearly independent branch retinal vein occlusion, or anterior ischemic optic 1726 
neuropathy. 1727 
Table 5 indicates the precision with which the SCORE Study will be able to estimate rates 1728 
of safety events at the end of the trial.  Three sample sizes are provided in Table 5:  1729 
• N=162: within each study arm. 1730 
• N=324: pooling the 1 mg and 4 mg intravitreal injection arms within  CRVO or 1731 
BRVO disease area OR pooling the 1 mg or 4 mg intravitreal injection arm across  1732 
each disease area.  1733 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 62 • N=648: pooling the 1 mg and 4 mg intravitr eal injection arms across  each disease 1734 
area.  1735 
For example, if the true rate is 0.25 and the sample size is 162, the 10% quantile for the 1736 
lower 95% confidence limits is 0.15, and the 90% quantile for the upper 95% confidence 1737 
limit and half -width are 0.36 and 0.07, respectively. 1738 
 1739 
Table 5:  90% limits for 95% confidence intervals of rates of safety events,  1740 
as a function of the true rate p and the sample size N 1741 
 1742 
 N=162  N=324  N=648  
P Lower 
CL Upper 
CL Half 
width  Lower 
CL Upper 
CL Half -
width  Lower 
CL Upper 
CL Half-
width  
0.01 0.00 0.05 0.02 0.00 0.04 0.02 0.00 0.03 0.01 
0.03 0.00 0.09 0.04 0.01 0.07 0.02 0.01 0.06 0.02 
0.05 0.01 0.13 0.04 0.02 0.10 0.03 0.03 0.08 0.02 
0.1 0.03 0.19 0.05 0.05 0.16 0.04 0.06 0.14 0.03 
0.15 0.07 0.25 0.06 0.09 0.22 0.04 0.11 0.20 0.03 
0.25 0.15 0.37 0.07 0.18 0.33 0.05 0.20 0.31 0.03 
0.5 0.37 0.63 0.08 0.41 0.59 0.06 0.44 0.57 0.04 
 1743 
6.6 Secondary Efficacy Outcomes  1744 
Secondary efficacy outcomes will be analyzed by comparing each triamcinolone group (4 1745 
mg or 1 mg) to standard care as well as by comparing 4 mg vs 1 mg intravitreal 1746 
triamcinolone for the secondary efficacy outcome variables listed below.  The secondary 1747 
efficacy outcomes include the following: 1748 
• Change between baseline and each efficacy outcome assessment visit in best - 1749 
corrected ETDRS visual acuity score (e.g., mean change from baseline in visual 1750 
acuity, distribution of change from baseline in visual acuity based on clinically 1751 
meaningful cut points of improvement or worsening of visual acuity). 1752 
• Change in calculated retinal thickening as assessed by optical coherence 1753 
tomography. 1754 
• Change in retinal thickness at the center of the macula as assessed by stereoscopic 1755 
color fundus photography. 1756 
• Change in area of retinal thickening as assessed by stereoscopic color fundus 1757 
photography.  1758 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 63  1759 
6.7 Statistical Guidelines for Interim Monitoring by the DSMC  1760 
6.7.1 Interim Monitoring for Safety  1761 
The SCORE Study will use repeated confidence intervals to continuously monitor the 1762 
safety indicator variables mentioned in section 6.5.  Safety rates will be reported 1763 
separately in the two disease areas, but injection arms will be pooled to increase 1764 
accuracy of the estimates.   1765 
 1766 
6.7.2 Interim Monitoring for Efficacy  1767 
The primary efficacy outcome occurs at 12 months from the randomization visit.  The 1768 
recruitm ent pattern is unpredictable.  Information concerning the primary outcome 1769 
will accrue as participants complete their 12 -month visit and thus "information time" 1770 
is the percent of the 486 patients in each trial expected to have completed this visit. 1771 
 1772 
Of the Type I error (alpha) = .05 for each trial, alpha = 0.005 will be allocated for 1773 
interim monitoring and the remaining alpha = 0.045 will be reserved for the final 1774 
analysis.  With alpha =0.045 for the final analysis, the estimate of the sample size 1775 
does not need to be increased for interim monitoring.  Interim testing will be carried 1776 
out using the Lan-DeMets interim monitoring boundary with an O’Brien- Fleming - 1777 
type spending function where at most 0.005 cumulative alpha can be spent prior to the 1778 
final analysis.  The "height of the hurdle" is highest when the information fraction is 1779 
smallest and decreases as additional patients complete 12 months.  The "height of the 1780 
hurdle" can be calculated for each DSMC meeting based on the number of patients 1781 
expected to have completed the 12-month visit and the alpha spent by previous 1782 
"looks" by the DSMC.  With the specification that the total alpha for interim 1783 
monitoring is 0.005, the maximum amount the DSMC can "spend" is 0.005.  If the 1784 
DSMC looks more often, it will “spend” less per look. 1785 
 1786 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 64 Formally, if t is the information fraction, B(t) is the 2 -sided cumulative O’Brien - 1787 
Fleming -type spending function of Lan & DeMets with final value B(1) = 0.005, and 1788 
S(t) is the two -sided cumulative spending function used by SCORE, then 1789 
 ( ) for 0 1()0.05 for 1Bt tStt≤< ==  1790 
 1791 
At each interim inspection, the three comparisons will be made using the Lan- DeMets 1792 
methodology, and the results combined using Hochberg’s sequentially rejective 1793 
procedure as described in the MOPP, section 6.4. 1794 
6.7.3 Interim Monit oring for Futility  1795 
The DSMC will consider futility as well as safety and efficacy.  One method of 1796 
statistically assessing futility is to use conditional power to estimate the likelihood of 1797 
statistical significance given the observed efficacy results and various possible 1798 
choices for the remaining results.   1799 
 1800 
6.7.4 Analyses and Results Requested to be Considered Prior to 1801 
Recommending Early Termination  1802 
 1803 
Before recommending early termination, the DSMC will consider: 1804 
• internal consistency of primary and secondary resul ts 1805 
• internal consistency of primary and secondary results by subgroups 1806 
defined by baseline characteristics (e.g. visual acuity categories, categories 1807 
based on length of history of CRVO or BRVO, and time period of 1808 
enrollment)  1809 
• distribution of baseline prognostic factors among the three groups 1810 
(standard care, 4 mg, 1 mg) 1811 
• consistency of primary and secondary results across clinical centers and 1812 
among centers enrolling larger numbers of patients 1813 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 65 • possible bias in assessment of primary and secondary response variabl es, 1814 
particularly visual acuity, given the unmasked implementation of standard 1815 
care versus intravitreal triamcinolone  1816 
• possible impact of missing data from missed patient visits for assessment 1817 
of the primary and secondary response variables 1818 
• possible differences in concomitant interventions or medications. 1819 
6.7.5 Study Timeline and DSMC Data Reviews  1820 
The DSMC will meet to review study data starting in November 2004, and every 6 1821 
months until 3- year follow -up is concluded on all study participants.  Table 6 depicts 1822 
the fractions of the population enrolled, with 1 year follow-up, and with 3 year 1823 
follow-up, assuming that enrollment is constant, starts in August 2004, and takes 18 1824 
months.  Under this assumption, there will be 10 DSMC meetings.  Formal interim 1825 
inspection for 1- year efficacy will take place only during the four meetings when the 1826 
information fraction is nonzero, that is, in November and May of 2005 and 2006. 1827 
 1828 
Table 6:  Study Timeline for DSMC Data Reviews  1829 
 1830 
Date of DSMC Meeting  Fraction  
Enrolled  With 1 -year 
follow -up With 3 -year 
follow -up 
November 2004  2/9   
May 2005  5/9   
November 2005  8/9 2/9  
May 2006  1 5/9  
November 2006   8/9  
May 2007   1  
November 2007    2/9 
May 2008    5/9 
November 2008    8/9 
May 2009    1 
 1831 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 66 7. Confidentiality and Access to Sourc e Data / Documents  1832 
The investigators will maintain the highest degree of confidentiality permitted for the clinical and 1833 
research information obtained from participants in this clinical study.  Medical and research 1834 
records should be maintained in the strictest confidence.  However, as part of the quality 1835 
assurance and legal responsibilities of an investigator, the site must permit authorized 1836 
representatives of the sponsor(s), the SCORE Coordinating Center, and regulatory agencies to 1837 
examine (and when permitt ed or required by applicable law, to copy) clinical records for the 1838 
purposes of quality assurance reviews, audits and evaluation of the study safety and progress. 1839 
Unless required by the law, no copying of records with personally identifying information wil l be 1840 
permitted.  Only the coded identity associated with documents or other participant data may be 1841 
copied (obscuring any personally identifying information) or transmitted to the SCORE 1842 
Coordinating Center.  Authorized representatives as noted above are bound to maintain the strict 1843 
confidentiality of medical and research information that may be linked to identified individuals. 1844 
The site will normally be notified in advance of monitoring and auditing visits. 1845 
 1846 
8. Summary of Good Clinical Practice Compliance 1847 
This trial will be conducted in accordance with Good Clinical Practice (GCP) using the guidance 1848 
documents and practices offered by ICH and FDA, and in accordance with the Declarations of 1849 
Helsinki and the policies and procedures for the SCORE Coordinating Ce nter at The EMMES 1850 
Corporation.  This study will also comply with the regulations under 21 CFR Parts 50, 54, 56, 1851 
and 312 under an IND application authorized by FDA.  1852 
 1853 
8.1 Investigator Responsibilities (Form FDA-1572) 1854 
A Statement of Investigator (Form FDA -1572) including the names of all of the 1855 
sub-investigators and selected key study personnel (e.g., pharmacist, study nurse and/or 1856 
study Coordinator, ophthalmic technician or optometric staff may be listed if desired) 1857 
directly involved in the study will be completed and signed by the Principal Investigator at 1858 
each site. The general responsibilities of the Investigator as acknowledged on the Form 1859 
FDA -1572 are governed under the regulations in 21 CFR  Parts 50, 54, 56, 312, and HIPAA. 1860 
 The study drug or test article may be administered only in accordance with the approved 1861 
protocol and under the supervision of the Investigator or a sub- investigator listed on this 1862 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 67 form.  The Investigator must maintain accurate and complete study records, including 1863 
records for disposi tion of the test article, and an accurate and complete record of all 1864 
submissions made to and received from the local Institutional Review Board (IRB) or 1865 
Independent Ethics Committee (IEC), including a copy of all reports and documents 1866 
submitted.  Adverse e xperiences that are reported to the FDA as IND Safety Reports must 1867 
be submitted promptly to the local IRB/IEC and the SCORE Coordinating Center. 1868 
 1869 
Progress reports must be submitted by the Investigator to the IRB/IEC at least once per 1870 
year.  The IRB/IEC mus t be promptly notified of completion or termination of the study.  1871 
Within three months of study completion or termination, a final report from the Investigator 1872 
must be provided to the IRB/IEC. 1873 
 1874 
The curriculum vitæ (CV) or a résumé for each investigator, sub-investigator, and key study 1875 
personnel must also be supplied if named on the Form FDA-1572.  This form and related 1876 
CVs must be supplied to the SCORE Coordinating Center prior to initiating the trial at each 1877 
site.  When necessary due to personnel changes, updated versions of the Form FDA-1572 1878 
must be forwarded to the SCORE Coordinating Center and copies of all versions must be 1879 
maintained in study records at each site.  Any CV or résumé collected at the beginning of a 1880 
study should be current, and would need to be updated during the study only if substantial 1881 
changes or additions are warranted (e.g., change of position or affiliation, certifications or 1882 
licensure, or significant new publications relevant to the study protocol). 1883 
 1884 
8.2 Human Subjects Protection  1885 
8.2.1 Institutional Review Board or Independent Ethics Committee  1886 
Each participating institution must have an IRB or IEC constituted and operating in 1887 
accordance with the regulations under 21 CFR Part 56 and authorized by the 1888 
institution to review and approved materials for this trial.  Because of the use of US 1889 
Federal funds in this trial, all participating institutions must have a current Assurance 1890 
of Compliance (either FWA or MPA) regarding their IRB/IEC on file with the DHHS 1891 
Office of Human Research Protections (OHRP) before any award can be made to that 1892 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 68 institution and before participants may be enrolled in the trial.  In addition, each 1893 
reviewing IRB or IEC must be registered with OHRP.  A list of IRB/IEC voting 1894 
members, their titles or occupations, and their institutional affiliations, as well as a 1895 
copy of the Assurance of Compliance, must be kept available by the institution for 1896 
inspection and copying by authorized study monitors, auditors, and regulatory 1897 
officials.  1898 
 1899 
8.3 Data Handling and Recordkeeping  1900 
The P rincipal Investigator at the Participating Clinical Center is responsible for maintaining 1901 
adherence to study procedures within the clinic.  He or she must spend adequate time at the 1902 
clinic observing study procedures and must hold regular discussions with s taff, either 1903 
one-to-one or in-group meetings, to review various aspects of the study and to solve 1904 
problems that may arise.  Other clinic staff members have a responsibility to report to the PI 1905 
problems that could affect the quality of the data.  The PI wil l designate one staff member 1906 
to be the Clinic Coordinator for the clinic, with specific responsibility for reporting 1907 
problems that have affected or can potentially affect the quality of data collected.  1908 
 1909 
The Clinic Coordinator should be thoroughly familiar with clinic activities and equipment 1910 
and the MOPP.  The Clinic Coordinator should maintain an up- to-date copy of the MOPP 1911 
close at hand and encourage all clinic personnel to consult it frequently.  During Full Group 1912 
Meetings the Clinic Coordinators will ha ve the opportunity to meet with the Protocol 1913 
Monitor to discuss mutual problems. 1914 
 1915 
8.3.1 Case Report Forms  1916 
Clinical data will be entered on electronic Case Report Forms (CRFs) in accordance 1917 
with the procedures specified in the current MOPP and Data Management Handbook 1918 
(DMH) for this trial.  1919 
 1920 
8.3.2 Data Transmittal 1921 
The primary method of data transmittal to the SCORE Coordinating Center will be via 1922 
the secure AdvantageEDC maintained by The EMMES Corporation.  The current 1923 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 69 MOPP, DMH and access to the AdvantageEDC  are available to authorized users via 1924 
the SCORE DCC Internet web site, located at http://www.emmes.com/  where an 1925 
assigned username and password are required for access.  All data transfers between 1926 
the investigational s ite and SCORE DCC via the AdvantageEDC are encrypted using 1927 
SSL technologies to assure confidential data transfer.  1928 
 1929 
8.4 Professional Licensure 1930 
Physicians must provide evidence of current medical licensure applicable to the study 1931 
location(s) if they are practicing medicine and undertake to diagnose and/or treat 1932 
participants (including administration of the test article) in this study.  A physician who is a 1933 
site Principal Investigator must also provide evidence of ophthalmology training before 1934 
study initiatio n. 1935 
 1936 
8.5 Human Subjects Protection Training  1937 
Documented training is required for each of the key personnel in the ethical conduct of 1938 
clinical studies and in the protection of human subjects.  1939 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 70 9. References  
1. The Branch Vein Occlusion Study Group.  Argon laser photocoagulation for macular 
edema in branch vein occlusion.  Am J Ophthalmol 1984;98:271-282. 
2. Central Vein Occlusion Study Group.  Baseline and early natural history report.  The Central Vein Occlusion Study.  Arch Ophthalmol 1993:111:1087-1095. 
3. The Cent ral Vein Occlusion Study Group.  Natural history and clinical management of 
central retinal vein occlusion.  Arch Ophthalmol 1997;115:486-491. 
4. The Central Vein Occlusion Study Group.  Evaluation of grid pattern photocoagulation for macular edema in central  vein occlusion.  The Central Vein Occlusion Study Group 
M Report.  Ophthalmology 1995;102(10):1425-1433. 
5. Opremcak EM and Bruce RA. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy. A prospective review of 15 cases. Retina 1999;19:1-5. 
6. Green WR, Chan CC, Hutchins GM, Terry JM.  Central Retinal Vein Occlusion:  A prospective histopathologic study of 29 eyes in 28 cases.  Trans Am Ophthalmol Soc 1981;79:371-422. 
7. Frangieh GT, Green WR, Barraquer -Somers E, Finkelstein D.  Histopathologic study of 
nine branch retinal vein occlusions.  Arch Ophthalmol 1982;100:1132-1140. 
8. Hockley DJ, Tripathi RC, Ashton N.  Experimental branch vein occlusion in rhesus monkeys. III.  Histopathological and electron microscopical studies.  Br J Ophthalmol 1979;63:393-411. 
9. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LEH, King GL.  Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta- isoform -selective inhibitor.  Diabetes 1997;46:1473-1480. 
10. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW.  Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1.  J Biol Chem 1999;274:23463-23467. 
11. Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF.  Tumor cells secrete a vascular permeability factor (VPF) that promotes accumulation of ascites fluid. Science 1983;219:983-985. 
12. Vinores SA, Youssri AI, Luna JD, Chen Y-S, Bhargave S, Vinores MA, Schoenfeld C-L, Peng B, Chan CH-CH, LaRochelle W, Green WR, Campochiaro PA.  Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental  retinal disease.  Histol Histopathol 1997;12:99-109. 
13. Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E.  Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998;105:412-416. 
14. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D’Amore PA, Miller JW.  Inhibition of vascular endothelial growth factor prevents retinal 
ischemia -associated iris neovascularization in a nonhuman primate.  Arch Ophthalmol 
1996;114:66-71. 
15. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M.  Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells.  Euro J Pharmacol 1998;341:309-315. 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 71 16. Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P, Perruchoud AP. 
Induction of vascular endothelial growth factor by platelet- activating factor and platelet -
derived growth-factor is downregulated by corticosteroids.  Am J Resp Cell Mol Biol 1997;16:398-406. 
17. McCuen B, Bessler M, Tano Y, Chandler D, Machemer R.  The lack of toxicity of 
intravitreally administered triamcinolone acetonide.  Am J Ophthalmol 1981;91:785-788. 
18. Schindler RH, Chandler DB, Thresher R, Machemer R.  The clearance of intravitreal trimcinolone acetonide.  Am J Ophthalmol 1982;93:415-17. 
19. Scholes GN, O’Brien WJ, Abrams GW, Kubicek MF.  Clearance of triamcinolone from vitreous.  Arch Ophthalmol 1985;103:1567-1569. 
20. Folkman J, Ingber DE. Angiostatic steroids.  Ann Surg 1987;206:374-383. 
21. Diaz -Flores L, Gutierrez R, Varela H. Angio genesis:  an update.  Histol Histopathol 
1994;9:807-843. 
22. Yoshikawa K, Kotake S, Ichiishi A, Sasamoto Y, Kosaka S, Matsuda H.  Posterior sub-Tenon injections of repository corticosteroids in uveitis patients with cystoid macular edema.  Jap J Ophthalmol 1995;39:71-76. 
23. Thach AB, Dugel PU, Flindall RJ, Sipperley JO, Sneed SR.  A comparison of retrobulbar versus sub- Tenon’s corticosteroid therapy for cystoid macular edema refractory to topical 
medications.  Ophthalmology 1997;104:2003-2008. 
24. Tano Y, Chandler D, Machemer R.  Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide.  Am J Ophthalmol 1980;90:810-816. 
25. Machemer R, Sugita G, Tano Y.  Treatment of intraocular proliferations with intravitreal steroids.  Tr Am Ophth Soc 1979;77:171-178. 
26. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL.  The effects of intravitreal triamcinolone acetonide on experimental pre- retinal neovascularization.  Graefe’s Arch 
Clin Exp Ophthalmol 1993;231:34-40. 
27. Danis RP, Bingaman DP, Yang Y, Ladd B.  Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide.  Ophthalmology 1996;103:2099-2104. 
28. Jonas JB, Hayler JK, Panda- Jonas S. Intravitreal injection of crystalline cortisone as 
adjunctive treatment of proliferative vitreoretinopathy.  Br J Ophthalmol 2000;84:1064-1067. 
29. Penfold PL, Gyory JF, Hunyor AB, Billson FA.  Exudative macular degeneration and intravitreal triamcinolone.  A pilot study. Aust N Z J Ophthalmol 1995;23:293-298. 
30. Challa JK, Gi llies MC, Penfold PL, Gyory JF, Hunyor ABL, Billson FA.  Exudative 
macular degeneration and intravitreal triamcinolone:  18 -month follow-up.  Aust N Z J 
Ophthalmol 1998;26:277-281. 
31. Danis RP, Ciulla TA, Pratt LM, Anliker W.  Intravitreal triamcinolone aceto nide in 
exudative age-related macular degeneration.  Retina 2000;20:244-250. 
32. Jonas JB and Sofker A.  Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema.  Am J Ophthalmol 2001;132:425-427. 
33. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema.   Ophthalmology 
2002;109:920-927. 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 72 34. Martidis A, Rogers AH, Greenberg PB, Ip MS, Duker JS, Reichel E, Baumal CR, 
Puliafito CA.  Intrav itreal triaminoclone acetonide for refractory diabetic macular edema. 
Invest Ophthalmol Vis Sci (Suppl) 42(4):S741, 2001. 
35. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E.  Intravitreal triamcinolone acetonide for macular oedema due to central reti nal vein occlusion.  Br J Ophthalmol 
2002;86:247-248. 
36. Ip MS, Kumar KS.  Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion.  Arch Ophthalmol 2002;120:1217-1219. 
37. Jonas JB, Kreissig I, Degenring RF.  Intr avitreal triamcinolone acetonide as treatment of 
macular edema in central retinal vein occlusion.  Graefe’s Arch Clin Exp Ophthalmol 2002;240:782-783. 
38. Park CH, Jaffe GJ, Fekrat S.  Intravitreal triamcinolone in eyes with cystoid macular 
edema associated wi th central retinal vein occlusion. Am J Ophthalmol 2003;136:419-425. 
39. Wingate RJ, Beaumont PE.  Intravitreal triamcinolone acetonide and elevated intraocular pressure.  Aust NZ J Ophthalmol 1999;27:431-432. 
40. Jonas JB, Hayler JK, Sofker A, Panda-Jones S.  Reg ression of neovascular iris vessels by 
intravitreal injection of crystalline cortisone. J Glaucoma 2001:10:284-287. 
41. Jonas JB, Kreissig I, Sofker A, Degenring RF.  Intravitreal injection of triamcinolone for diffuse diabetic macular edema.  Arch Ophthalmol 2003:121:57-61. 
42. Bergh F.  Binding characteristics of the glucocorticoid receptor in peripheral blood lymphocytes in multiple sclerosis. J. Neurol 1999;246:292-8. 
43. Schottelius A. Higher expression of glucocorticoid receptor in peripheral mononuclear cells in  inflammatory bowel disease. Am J Gastroenterol 1994; 95:2000. 
44. Armaly MF.  Statistical attributes of the steroid hypertensive response in the clinically normal eye.  Invest Ophthalmol Vis Sci 1965;4:187-197. 
45. Becker B.  Intraocular pressure response to topi cal corticosteroids. Invest Ophthalmol Vis 
Sci 1965;4:198-205. 
46. Goldberg I.  Ocular inflammatory and corticosteroid-induced glaucoma. In Ophthalmology (eds. Yanoff M and Duker JS). pp.12.17.1-12.17.6. Mosby International Ltd., London, UK 1999. 
47. Cumming RG, Mitchell P, Leeder SR.  Use of inhaled corticosteroids and the risk of cataracts.  New Engl J Med 1997;337:8-14. 
48. Butcher JM. Austin M, McGalliard, Bourke RD. Bilateral cataracts and glaucoma induced by long term use of steroid eye drops.  BMJ 1994;309:43.  
49. Garbe E, Suissa S, LeLorier J.  Association of inhaled corticosteroids use with cataract extraction in elderly patients.  JAMA 1998;280:539-543. 
50. Aaberg TM Jr, Flynn HW Jr.  Nosocomial postoperative endophthalmitis. Invest Ophthalmol Vis Sci 1996; 37: S775. 
51. Endophthalmitis Vitrectomy Study Group. Results of the endophthalmitis vitrectomy study. Arch Ophthalmol 1995;113:1479-1496. 
52. Hida T, Chandler D, Arena J, Machemer R.  Experimental and clinical observations of the intraocular toxicity off commercial cortic osteroid preparations.  Am J Ophthalmol 
1986; 101:190-195.  
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 73 53. Musch DC, Lichter PR, Guire KE, Standardi CL and the CIGTS Study Group.  The 
Collaborative Initial Glaucoma Treatment Study, Study Design, Methods, and Baseline Characteristics of Enrolled Patient s.  Ophthalmology 1999;106:653-662. 
 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 74 10. Appendix I  
 
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study  February 10, 2008  
 
 
 
Version 7.0 CONFIDENTIAL   Page 75 Appendix 1:  Scheduled Study Evaluations  
 Baseline  4-month interval follow -up visits  Safety2 
M4 M8 M12  M16  M20  M24  M28  M32  M36  D4 M1 
Informed 
consent  X            
Urine 
pregnancy test  X3            
Medical/ocular 
history  X3            
Blood pressure  X3   X   X   X   
Visual acuity  X4,5 X5 X5 X5 X5 X5 X5 X5 X5 X5 X7 X7 
Manifest 
refraction  X5 X5  X5   X5   X5   
IOP X3,5 X5 X5 X5 X5 X5 X5 X5 X5 X5 X7 X7 
Ophthalmic 
examination8 X3,5 X5 X5 X5 X5 X5 X5 X5 X5 X5 X7 X7 
Lens 
assessment9 X3,5 X5  X5   X5   X5   
Fundus photos              
Study Eye  M7F3 M3F  M3F  M7F  M3F  M3F  M7F  M3F  M3F  M7F    
Non-study Eye  M3F3   M3F    M3F    M3F    
FA X3 X  X   X      
OCT  X5,10 X5 X6 X5 X6 X6 X5 X6 X6 X5   
Steroid 
injection 
/Laser1 X X X X X X X X X    
M= month    M7F= Modified 7- Field photos  
Q= every      M3F= Modified 3- Field photos  
D= day  
 
1 Retreatment with steroid injections or laser photocoagulation (if applicable) should be administered at 4 -month intervals 
unles s there are specific reasons not to treat in which case the investigator may decide to postpone treatment (see protocol 
section 4.8.3).  
2 Safety visits are performed at Day 4 and Month 1 after each injection.  
3 To be performed within 21 days prior to randomization.  
4 To be performed within 8 days prior to randomization  
5 Examination data to be collected on both eyes.  
6 Examination data to be collected on study eye only.  
7 Examination data to be collected on the injected eye only.  
8 Examination includes bo th a dilated fundus examination and a slit- lamp examination.  
9 To be performed using the modified AREDS lens grading system.  
10 OCT measurements will be performed twice on the same day in both eyes.  This will occur within 21 days prior to 
randomization.  
 
Note:  Visit windows at M8, M16, M20, M28, M32 may be extended, if necessary, so that the visit 
occurs no sooner than 3.5 months from the last treatment. 